Back to Search Results
Image Place holder

Eric Haura, MD

Associate Center Director, Clinical Science
Senior Member, Department of Thoracic Oncology & Drug Discovery

 
Specialty: Medical Oncology
Sub Specialty: Medical Oncology
Program: Thoracic Oncology

Google Scholar Profile


Call 1-888-663-3488

Call 1-888-663-3488


Locations:
Overview

Cancer Focus: Lung Cancer, Mesothelioma, Thymoma

Dr. Eric Haura received his undergraduate degree in Biomedical Engineering from the Johns Hopkins University in 1990 and completed medical school at Duke University School of Medicine in 1994. He returned to Johns Hopkins and completed a residency program in internal medicine in 1997. He then went on to Duke to pursue a clinical fellowship in hematology and oncology and a research fellowship in genetics. He completed both programs in 2000. He joined the H. Lee Moffitt Cancer Center and Research Institute in the Department of Thoracic Oncology in 2000 and is currently a Senior Member. He is the Director of the Moffitt Lung Cancer Center of Excellence.  He led the CCSG Molecular Medicine Program for 10 years.  He is currently the Associate Center Director for Clinical Science.  Dr. Haura’s major contribution has been as a leader in advancing the field of translational cancer proteomics and molecular characterization of cancers using highly integrative mass spectrometry-based proteomics. He has characterized protein architectures that regulate tumor growth and response to therapy. He developed approaches to discern mechanisms of complex drugs in cancer allowing repurposing of drugs and expanded uses. He has published more than 200 papers in top-tier scientific journals including Science Signaling, Nature Chemical Biology, Proceedings of the National Academy of Sciences, Molecular Systems Biology, Journal of Clinical Oncology, and Cancer Research. He has received numerous grants through the National Cancer Institute, industry partners, and private foundations. He has served as a consultant for numerous pharmaceutical companies as well as lung cancer research centers. He is a member of the American Association of Cancer Research, the International Association for the Study of Lung Cancer, and the American Society of Clinical Oncology, and the Human Proteome Organization. He has served as a grant reviewer for the National Cancer Institute, American Cancer Society, and private lung cancer research foundations. He received the ASCO Advanced Clinical Research Award in 2007. He was named Moffitt Research Scientist of the Year in 2011 and was named Research Mentor of the Year in 2009. In 2014 he was inducted into the American Society of Clinical Investigation, one of the nation’s oldest and most respected honor societies for physician-scientists. Dr. Haura is an expert in the management of lung cancer. He has designed and executed numerous clinical trials exploring new agents for the treatment of lung cancer. He is interested in biomarkers to predict therapeutic responses in lung cancer and is active in developing molecular based therapeutic clinical trials. He has organized the department’s genome medicine strategy to bring precision medicine to the bedside and is interested in migrating new platforms to the bedside to assist in clinical decision making. 


Education & Training

Fellowship:

  • Duke University Medical Center - Hematology & Oncology
  • Duke University Medical Center - Genetics

Residency:

  • Johns Hopkins Hospital - Internal Medicine

Medical School:

  • Duke University School of Medicine - MD
Awards
Start Year: 2011 End Year: 2011 Researcher of the Year, Sponsor: H. Lee Moffitt Cancer Center & Research Institute
Start Year: 2003 End Year: 2003 Young Investigator's Award, Sponsor: 10th World Conference on Lung Cancer
Start Year: 2009 End Year: Research Mentor of the Year, Sponsor: Moffitt Cancer Center
Participating Trials

CLINICAL TRIAL 21129
A Phase 1/1b, Open-Label, Multicenter, Dose-Escalation Study of RMC-5552 Monotherapy in Adult Subjects with Relapsed/Refractory Solid Tumors
Condition: Multiple
Intervention: RMC-5552 ()
Open

CLINICAL TRIAL 21022
A Phase 1b/2, Master Protocol Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 510 (pINN sotorasib) in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation
Condition: Multiple
Intervention: AMG 404 (); AMG 510 (Sotorasib); FOLFIRI (); Not Applicable (); Panitumumab (); RMC-4630 (); Sotorasib (); Vectibix (Panitumumab)
Open

If you believe you are eligible for one of these trials or studies, please call
813-745-6100 or toll-free 1-800-679-0775.

Publications

  • Letson CT, Balasis ME, Newman H, Binder M, Vedder A, Kinose F, Ball M, Kruer T, Quintana A, Lasho TL, Finke CM, Almada LL, Grants JM, Zhang G, Fernandez-Zapico ME, Gaspar-Maia A, Lancet J, Komrokji R, Haura E, Sallman DA, Reuther GW, Karsan A, Rix U, Patnaik MM, Padron E. Targeting BET proteins downregulates miR-33a to promote synergy with PIM inhibitors in CMML. Clin Cancer Res. 2023 May. Pubmedid: 37223910.
  • Hu Q, Liao Y, Cao J, Fang B, Yun S, Kinose F, Haura E, Lawrence H, Doebele R, Koomen J, Rix U. Differential Chemoproteomics Reveals MARK2/3 as Cell Migration-Relevant Targets of the ALK Inhibitor Brigatinib. Chembiochem. 2023 Mar.e202200766. Pubmedid: 36922348.
  • Cornelissen R, Prelaj A, Sun S, Baik C, Wollner M, Haura EB, Mamdani H, Riess JW, Cappuzzo F, Garassino MC, Heymach JV, Socinski MA, Leu SY, Bhat G, Lebel F, Le X. Poziotinib in Treatment-Naive NSCLC Harboring HER2 Exon 20 Mutations: ZENITH20-4, A Multicenter, Multicohort, Open-Label, Phase 2 Trial (Cohort 4). J Thorac Oncol. 2023 Mar. Pubmedid: 36958688.
  • Ross KE, Zhang G, Akcora C, Lin Y, Fang B, Koomen J, Haura EB, Grimes M. Network models of protein phosphorylation, acetylation, and ubiquitination connect metabolic and cell signaling pathways in lung cancer. PLoS Comput Biol. 2023 Mar.19(3):e1010690. Pubmedid: 36996232. Pmcid: PMC10089347.
  • Liveringhouse CL, Latifi K, Asous AG, Lam NB, Rosenberg SA, Dilling TJ, MacMillan GV, Chiappori AA, Haura EB, Creelan B, Gray JE, Tanvetyanon T, Shafique MR, Saltos AN, Weiner AA, Clarke J, Kelsey CR, Kim S, Caudell JJ, Rose TA, Conejo-Garcia JR, Li J, Schell MJ, Antonia SJ, Perez BA. Dose Limiting Pulmonary Toxicity in a Phase 1/2 Study of Radiation and Chemotherapy with Ipilimumab Followed by Nivolumab for Patients With Stage 3 Unresectable Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2023 Jan. Pubmedid: 36657497.
  • Liao Y, Chin Chan S, Welsh EA, Fang B, Sun L, Schönbrunn E, Koomen JM, Duckett DR, Haura EB, Monastyrskyi A, Rix U. Chemical Proteomics with Novel Fully Functionalized Fragments and Stringent Target Prioritization Identifies the Glutathione-Dependent Isomerase GSTZ1 as a Lung Cancer Target. Acs Chem Biol. 2023 Feb.18(2):251-264. Pubmedid: 36630201.
  • Park K, Sabari JK, Haura EB, Shu CA, Spira A, Salgia R, Reckamp KL, Sanborn RE, Govindan R, Bauml JM, Curtin JC, Xie J, Roshak A, Lorenzini P, Millington D, Thayu M, Knoblauch RE, Cho BC. Management of infusion-related reactions (IRRs) in patients receiving amivantamab in the CHRYSALIS study. Lung Cancer. 2023 Apr.178:166-171. Pubmedid: 36868177.
  • Madanayake TW, Welsh EA, Darville LNF, Koomen JM, Chalfant CE, Haura EB, Robinson TJ. Inhibition of Epidermal Growth Factor Receptor Signaling by Antisense Oligonucleotides as a Novel Approach to Epidermal Growth Factor Receptor Inhibition. Nucleic Acid Ther. 2022 Oct.32(5):391-400. Pubmedid: 35861718. Pmcid: PMC9595651.
  • Chaft JE, Oezkan F, Kris MG, Bunn PA, Wistuba II, Kwiatkowski DJ, Owen DH, Tang Y, Johnson BE, Lee JM, Lozanski G, Pietrzak M, Seweryn M, Byun WY, Schulze K, Nicholas A, Johnson A, Grindheim J, Hilz S, Shames DS, Rivard C, Toloza E, Haura EB, McNamee CJ, Patterson GA, Waqar SN, Rusch VW, Carbone DP. Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial. Nat Med. 2022 Oct.28(10):2155-2161. Pubmedid: 36097216. Pmcid: PMC9556329.
  • Rusch VW, Nicholas A, Patterson GA, Waqar SN, Toloza EM, Haura EB, Raz DJ, Reckamp KL, Merritt RE, Owen DH, Finley DJ, McNamee CJ, Blasberg JD, Garon EB, Mitchell JD, Doebele RC, Baciewicz F, Nagasaka M, Pass HI, Schulze K, Johnson A, Bunn PA, Johnson BE, Kris MG, Kwiatkowski DJ, Wistuba II, Chaft JE, Carbone DP, Lee JM. Surgical results of the Lung Cancer Mutation Consortium 3 trial: A phase II multicenter single-arm study to investigate the efficacy and safety of atezolizumab as neoadjuvant therapy in patients with stages IB-select IIIB resectable non-small cell lung ca. J Thorac Cardiovasc Surg. 2022 Oct. Pubmedid: 36369159.
  • Chiappori AA, Creelan B, Tanvetyanon T, Gray JE, Haura EB, Thapa R, Barlow ML, Chen Z, Chen DT, Beg AA, Boyle TA, Castro J, Morgan L, Morris E, Aregay M, Hurtado FK, Manenti L, Antonia S. Phase I Study of Taminadenant (PBF509/NIR178), an Adenosine 2A Receptor Antagonist, with or without Spartalizumab (PDR001), in Patients with Advanced Non-Small Cell Lung Cancer. Clin Cancer Res. 2022 Jun.28(11):2313-2320. Pubmedid: 35254415. Pmcid: PMC9167697.
  • Wang J, Martin-Romano P, Cassier P, Johnson M, Haura E, Lenox L, Guo Y, Bandyopadhyay N, Russell M, Shearin E, Lauring J, Dahan L. Phase I Study of JNJ-74699157 in Patients with Advanced Solid Tumors Harboring the KRAS G12C Mutation. Oncologist. 2022 Jul.27(7):536-e553. Pubmedid: 35325211. Pmcid: PMC9255981.
  • Palve V, Knezevic CE, Bejan DS, Luo Y, Li X, Novakova S, Welsh EA, Fang B, Kinose F, Haura EB, Monteiro AN, Koomen JM, Cohen MS, Lawrence HR, Rix U. The non-canonical target PARP16 contributes to polypharmacology of the PARP inhibitor talazoparib and its synergy with WEE1 inhibitors. Cell Chem Biol. 2022 Feb.29(2):202-214.e7. Pubmedid: 34329582. Pmcid: PMC8782927.
  • Remsing Rix LL, Sumi NJ, Hu Q, Desai B, Bryant AT, Li X, Welsh EA, Fang B, Kinose F, Kuenzi BM, Chen YA, Antonia SJ, Lovly CM, Koomen JM, Haura EB, Marusyk A, Rix U. IGF-binding proteins secreted by cancer-associated fibroblasts induce context-dependent drug sensitization of lung cancer cells. Sci Signal. 2022 Aug.15(747):eabj5879. Pubmedid: 35973030. Pmcid: PMC9528501.
  • Majumder A, Hosseinian S, Stroud M, Adhikari E, Saller JJ, Smith MA, Zhang G, Agarwal S, Creixell M, Meyer BS, Kinose F, Bowers K, Fang B, Stewart PA, Welsh EA, Boyle TA, Meyer AS, Koomen JM, Haura EB. Integrated Proteomics-Based Physical and Functional Mapping of AXL Kinase Signaling Pathways and Inhibitors Define Its Role in Cell Migration. Mol Cancer Res. 2022 Apr.20(4):542-555. Pubmedid: 35022314. Pmcid: PMC8983558.
  • Mahajan S, Majumder A, Stewart PA, Chen YA, Adhikari E, Fang B, Yang Y, Lawrence H, Kinose F, Koomen JM, Haura EB. Deubiquitinase Vulnerabilities Identified through Activity-Based Protein Profiling in Non-Small Cell Lung Cancer. Acs Chem Biol. 2022 Apr.17(4):776-784. Pubmedid: 35311290.
  • Luo J, Ostrem J, Pellini B, Imbody D, Stern Y, Solanki HS, Haura EB, Villaruz LC. Overcoming KRAS-Mutant Lung Cancer. Am Soc Clin Oncol Educ Book. 2022 Apr.42:1-11. Pubmedid: 35412860.
  • Park K, Haura EB, Leighl NB, Mitchell P, Shu CA, Girard N, Viteri S, Han JY, Kim SW, Lee CK, Sabari JK, Spira AI, Yang TY, Kim DW, Lee KH, Sanborn RE, Trigo J, Goto K, Lee JS, Yang JC, Govindan R, Bauml JM, Garrido P, Krebs MG, Reckamp KL, Xie J, Curtin JC, Haddish-Berhane N, Roshak A, Millington D, Lorenzini P, Thayu M, Knoblauch RE, Cho BC. Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study. J Clin Oncol. 2021 Oct.39(30):3391-3402. Pubmedid: 34339292. Pmcid: PMC8791812.
  • Xiao T, Sun L, Zhang M, Li Z, Haura EB, Schonbrunn E, Ji H. Synthesis and structural characterization of a monocarboxylic inhibitor for GRB2 SH2 domain. Bioorg Med Chem Lett. 2021 Nov.51:128354. Pubmedid: 34506932. Pmcid: PMC8526398.
  • Solanki HS, Welsh EA, Fang B, Izumi V, Darville LNF, Stone B, Franzese R, Chavan S, Kinose F, Imbody D, Koomen JM, Rix U, Haura EB. Cell Type-specific Adaptive Signaling Responses to KRASG12C Inhibition. Clin Cancer Res. 2021 May.27(9):2533-2548. Pubmedid: 33619172.
  • Bertino EM, Gentzler RD, Clifford SE, Kolesar JM, Muzikansky A, Haura EB, Piotrowska Z, Camidge DR, Stinchcombe TE, Hann CL, Malhotra J, Villaruz LC, Paweletz CP, Lau CJ, Sholl LM, Takebe N, Moscow JA, Shapiro GI, Janne PA, Oxnard GR. Phase IB Study of Osimertinib in Combination with Navitoclax in EGFR-mutant NSCLC Following Resistance to Initial EGFR Therapy (ETCTN 9903). Clin Cancer Res. 2021 Mar.27(6):1604-1611. Pubmedid: 33376097. Pmcid: PMC7976451.
  • Shields MD, Hicks JK, Boyle TA, Haura EB, Creelan BC. Selpercatinib Overcomes CCDC6-RET-Mediated Resistance to Osimertinib. J Thorac Oncol. 2021 Mar.16(3):e15-e17. Pubmedid: 33641722.
  • Gordian E, Welsh EA, Gimbrone N, Siegel EM, Shibata D, Creelan BC, Cress WD, Eschrich SA, Haura EB, Muñoz-Antonia T. Correction: Transforming growth factor β-induced epithelial-to-mesenchymal signature predicts metastasis-free survival in non-small cell lung cancer. Oncotarget. 2021 Jun.12(13):1325. Pubmedid: 34194632. Pmcid: PMC8238243.
  • Kohale IN, Burgenske DM, Mladek AC, Bakken KK, Kuang J, Boughey JC, Wang L, Carter JM, Haura EB, Goetz MP, Sarkaria JN, White FM. Quantitative Analysis of Tyrosine Phosphorylation from FFPE Tissues Reveals Patient-Specific Signaling Networks. Cancer Res. 2021 Jul.81(14):3930-3941. Pubmedid: 34016623. Pmcid: PMC8286342.
  • Chen DT, Chan W, Thompson ZJ, Thapa R, Beg AA, Saltos AN, Chiappori AA, Gray JE, Haura EB, Rose TA, Creelan B. Utilization of target lesion heterogeneity for treatment efficacy assessment in late stage lung cancer. PLoS One. 2021 Jul.16(7):e0252041. Pubmedid: 34197475. Pmcid: PMC8248740.
  • Perez BA, Kim S, Wang M, Karimi AM, Powell C, Li J, Dilling TJ, Chiappori A, Latifi K, Rose T, Lannon A, MacMillan G, Saller J, Grass GD, Rosenberg S, Gray J, Haura E, Creelan B, Tanvetyanon T, Saltos A, Shafique M, Boyle TA, Schell MJ, Conejo-Garcia JR, Antonia SJ. Prospective Single-Arm Phase 1 and 2 Study: Ipilimumab and Nivolumab With Thoracic Radiation Therapy After Platinum Chemotherapy in Extensive-Stage Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2021 Feb.109(2):425-435. Pubmedid: 33002543. Pmcid: PMC8465780.
  • Creelan BC, Wang C, Teer JK, Toloza EM, Yao J, Kim S, Landin AM, Mullinax JE, Saller JJ, Saltos AN, Noyes DR, Montoya LB, Curry W, Pilon-Thomas SA, Chiappori AA, Tanvetyanon T, Kaye FJ, Thompson ZJ, Yoder SJ, Fang B, Koomen JM, Sarnaik AA, Chen DT, Conejo-Garcia JR, Haura EB, Antonia SJ. Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial. Nat Med. 2021 Aug.27(8):1410-1418. Pubmedid: 34385708. Pmcid: PMC8509078.
  • Haura EB, Hicks JK, Boyle TA. Erdafitinib Overcomes FGFR3-TACC3-Mediated Resistance to Osimertinib. J Thorac Oncol. 2020 Sep.15(9):e154-e156. Pubmedid: 32854916.
  • Stewart PA, Welsh EA, Fang B, Izumi V, Mesa T, Zhang C, Yoder S, Zhang G, Cen L, Pettersson F, Zhang Y, Chen Z, Cheng CH, Thapa R, Thompson Z, Avedon M, Wloch M, Fournier M, Fellows KM, Francis JM, Saller JJ, Boyle TA, Chen YA, Haura EB, Teer JK, Eschrich SA, Koomen JM. Managing a Large-Scale Multiomics Project: A Team Science Case Study in Proteogenomics. Methods Mol Biol. 2020 Sep.2194:187-221. Pubmedid: 32926368. Pmcid: PMC7771375.
  • Boyle TA, Khalil FK, Mino-Kenudson M, Sica GL, Moreira AL, Sholl LM, Knight MZ, Zhang L, Saller J, Varella-Garcia M, Berry LD, Chen H, Ellison KE, Rivard CJ, Kugler K, Wistuba II, Fujimoto J, Kwiatkowski DJ, Bunn PA, Kris MG, Haura EB, Hirsch FR. Round Robin Evaluation of MET Protein Expression in Lung Adenocarcinomas Improves Interobserver Concordance. Appl Immunohistochem Mol Morphol. 2020 Oct.28(9):669-677. Pubmedid: 31876606. Pmcid: PMC7242128.
  • Ji X, Mukherjee S, Landi MT, Bosse Y, Joubert P, Zhu D, Gorlov I, Xiao X, Han Y, Gorlova O, Hung RJ, Brhane Y, Carreras-Torres R, Christiani DC, Caporaso N, Johansson M, Liu G, Bojesen SE, Le Marchand L, Albanes D, Bickeböller H, Aldrich MC, Bush WS, Tardon A, Rennert G, Chen C, Byun J, Dragnev KH, Field JK, Kiemeney LF, Lazarus P, Zienolddiny S, Lam S, Schabath MB, Andrew AS, Bertazzi PA, Pesatori AC, Diao N, Su L, Song L, Zhang R, Leighl N, Johansen JS, Mellemgaard A, Saliba W, Haiman C, Wilkens L, Fernandez-Somoano A, Fernandez-Tardon G, Heijden EHFMV, Kim JH, Davies MPA, Marcus MW, Brunnström H, Manjer J, Melander O, Muller DC, Overvad K, Trichopoulou A, Tumino R, Goodman GE, Cox A, Taylor F, Woll P, Wichmann E, Muley T, Risch A, Rosenberger A, Grankvist K, Johansson M, Shepherd F, Tsao MS, Arnold SM, Haura EB, Bolca C, Holcatova I, Janout V, Kontic M, Lissowska J, Mukeria A, Ognjanovic S, Orlowski TM, Scelo G, Swiatkowska B, Zaridze D, Bakke P, Skaug V, Butler LM, Offit K, Srinivasan P, Bandlamudi C, Hellmann MD, Solit DB, Robson ME, Rudin CM, Stadler ZK, Taylor BS, Berger MF, Houlston R, McLaughlin J, Stevens V, Nickle DC, Obeidat M, Timens W, Artigas MS, Shete S, Brenner H, Chanock S, Brennan P, McKay JD, Amos CI. Protein-altering germline mutations implicate novel genes related to lung cancer development. Nat Commun. 2020 May.11(1):2220. Pubmedid: 32393777. Pmcid: PMC7214407.
  • Vander Velde R, Yoon N, Marusyk V, Durmaz A, Dhawan A, Miroshnychenko D, Lozano-Peral D, Desai B, Balynska O, Poleszhuk J, Kenian L, Teng M, Abazeed M, Mian O, Tan AC, Haura E, Scott J, Marusyk A. Resistance to targeted therapies as a multifactorial, gradual adaptation to inhibitor specific selective pressures. Nat Commun. 2020 May.11(1):2393. Pubmedid: 32409712. Pmcid: PMC7224215.
  • Polaske NW, Kelly BD, Smith MA, Haura EB, Belosludtsev YY. Fully Automated Protein Proximity Assay in Formalin-Fixed, Paraffin-Embedded Tissue Using Caged Haptens. Bioconjug Chem. 2020 Jun.31(6):1635-1640. Pubmedid: 32395983.
  • Li Q, Fisher K, Meng W, Fang B, Welsh E, Haura EB, Koomen JM, Eschrich SA, Fridley BL, Chen YA. GMSimpute: a generalized two-step Lasso approach to impute missing values in label-free mass spectrum analysis. Bioinformatics. 2020 Jan.36(1):257-263. Pubmedid: 31199438. Pmcid: PMC6956786.
  • Boyle TA, Quinn GP, Schabath MB, Muñoz-Antonia T, Saller JJ, Duarte LF, Hair LS, Teer JK, Chiang DY, Leary R, Wong CC, Savchenko A, Singh AP, Charette L, Mendell K, Gorgun G, Antonia SJ, Chiappori AA, Creelan BC, Gray JE, Haura EB. A community-based lung cancer rapid tissue donation protocol provides high-quality drug-resistant specimens for proteogenomic analyses. Cancer Med. 2020 Jan.9(1):225-237. Pubmedid: 31747139. Pmcid: PMC6943158.
  • Torrente L, Prieto-Farigua N, Falzone A, Elkins CM, Boothman DA, Haura EB, DeNicola GM. Inhibition of TXNRD or SOD1 overcomes NRF2-mediated resistance to β-lapachone. Redox Biol. 2020 Feb.30:101440. Pubmedid: 32007910. Pmcid: PMC6997906.
  • Fang B, Izumi V, Rix LLR, Welsh E, Pike I, Reuther GW, Haura EB, Rix U, Koomen JM. Lowering Sample Requirements to Study Tyrosine Kinase Signaling Using Phosphoproteomics with the TMT Calibrator Approach. Proteomics. 2020 Dec.20(24):e2000116. Pubmedid: 32865326. Pmcid: PMC7771371.
  • Simmons VN, Sutton SK, Meltzer LR, Martinez U, Palmer AM, Meade CD, Jacobsen PB, McCaffrey JC, Haura EB, Brandon TH. Preventing smoking relapse in patients with cancer: A randomized controlled trial. Cancer. 2020 Dec.126(23):5165-5172. Pubmedid: 32902856. Pmcid: PMC7771373.
  • Mohamed E, Sierra RA, Trillo-Tinoco J, Cao Y, Innamarato P, Payne KK, de Mingo Pulido A, Mandula J, Zhang S, Thevenot P, Biswas S, Abdalla SK, Costich TL, Hänggi K, Anadon CM, Flores ER, Haura EB, Mehrotra S, Pilon-Thomas S, Ruffell B, Munn DH, Cubillos-Ruiz JR, Conejo-Garcia JR, Rodriguez PC. The Unfolded Protein Response Mediator PERK Governs Myeloid Cell-Driven Immunosuppression in Tumors through Inhibition of STING Signaling. Immunity. 2020 Apr.52(4):668-682.e7. Pubmedid: 32294407. Pmcid: PMC7207019.
  • Sumi NJ, Ctortecka C, Hu Q, Bryant AT, Fang B, Remsing Rix LL, Ayaz M, Kinose F, Welsh EA, Eschrich SA, Lawrence HR, Koomen JM, Haura EB, Rix U. Divergent Polypharmacology-Driven Cellular Activity of Structurally Similar Multi-Kinase Inhibitors through Cumulative Effects on Individual Targets. Cell Chem Biol. 2019 Sep.26(9):1240-1252.e11. Pubmedid: 31257184. Pmcid: PMC6754293.
  • Xie M, Zheng H, Madan-Lala R, Dai W, Gimbrone NT, Chen Z, Kinose F, Blackstone SA, Smalley KSM, Cress WD, Haura EB, Rix U, Beg AA. MEK Inhibition Modulates Cytokine Response to Mediate Therapeutic Efficacy in Lung Cancer. Cancer Res. 2019 Nov.79(22):5812-5825. Pubmedid: 31362929. Pmcid: PMC6881545.
  • Gray JE, Saltos AN, Tanvetyanon T, Haura EB, Creelan BC, Antonia SJ, Shafique M, Zheng H, Dai W, Saller JJ, Chen Z, Tchekmedyian N, Goas K, Thapa R, Boyle TA, Chen DT, Beg AA. Phase I/Ib Study of Pembrolizumab Plus Vorinostat in Advanced/Metastatic Non-Small Cell Lung Cancer. Clin Cancer Res. 2019 Nov.25(22):6623-6632. Pubmedid: 31409616. Pmcid: PMC7234799.
  • Chiappori AA, Williams CC, Gray JE, Tanvetyanon T, Haura EB, Creelan BC, Thapa R, Chen DT, Simon GR, Bepler G, Gabrilovich DI, Antonia SJ. Randomized-controlled phase II trial of salvage chemotherapy after immunization with a TP53-transfected dendritic cell-based vaccine (Ad.p53-DC) in patients with recurrent small cell lung cancer. Cancer Immunol Immun. 2019 Mar.68(3):517-527. Pubmedid: 30591959. Pmcid: PMC6426813.
  • Li Y, Xiao X, Bossé Y, Gorlova O, Gorlov I, Han Y, Byun J, Leighl N, Johansen JS, Barnett M, Chen C, Goodman G, Cox A, Taylor F, Woll P, Wichmann HE, Manz J, Muley T, Risch A, Rosenberger A, Han J, Siminovitch K, Arnold SM, Haura EB, Bolca C, Holcatova I, Janout V, Kontic M, Lissowska J, Mukeria A, Ognjanovic S, Orlowski TM, Scelo G, Swiatkowska B, Zaridze D, Bakke P, Skaug V, Zienolddiny S, Duell EJ, Butler LM, Houlston R, Artigas MS, Grankvist K, Johansson M, Shepherd FA, Marcus MW, Brunnström H, Manjer J, Melander O, Muller DC, Overvad K, Trichopoulou A, Tumino R, Liu G, Bojesen SE, Wu X, Le Marchand L, Albanes D, Bickeböller H, Aldrich MC, Bush WS, Tardon A, Rennert G, Teare MD, Field JK, Kiemeney LA, Lazarus P, Haugen A, Lam S, Schabath MB, Andrew AS, Bertazzi PA, Pesatori AC, Christiani DC, Caporaso N, Johansson M, McKay JD, Brennan P, Hung RJ, Amos CI. Genetic interaction analysis among oncogenesis-related genes revealed novel genes and networks in lung cancer development. Oncotarget. 2019 Mar.10(19):1760-1774. Pubmedid: 30956756. Pmcid: PMC6442994.
  • Chen DT, Schell MJ, Fulp WJ, Pettersson F, Kim S, Gray JE, Haura EB. Application of Bayesian predictive probability for interim futility analysis in single-arm phase II trial. Transl Cancer Res. 2019 Jul.8(Suppl 4):S404-S420. Pubmedid: 31456910. Pmcid: PMC6711387.
  • Gordian E, Welsh EA, Gimbrone N, Siegel EM, Shibata D, Creelan BC, Cress WD, Eschrich SA, Haura EB, Muñoz-Antonia T. Transforming growth factor β-induced epithelial-to-mesenchymal signature predicts metastasis-free survival in non-small cell lung cancer. Oncotarget. 2019 Jan.10(8):810-824. Pubmedid: 30783512. Pmcid: PMC6368226.
  • Ramello MC, Benzaïd I, Kuenzi BM, Lienlaf-Moreno M, Kandell WM, Santiago DN, Pabón-Saldaña M, Darville L, Fang B, Rix U, Yoder S, Berglund A, Koomen JM, Haura EB, Abate-Daga D. An immunoproteomic approach to characterize the CAR interactome and signalosome. Sci Signal. 2019 Feb.12(568). Pubmedid: 30755478. Pmcid: PMC6506216.
  • Stewart PA, Welsh EA, Slebos RJC, Fang B, Izumi V, Chambers M, Zhang G, Cen L, Pettersson F, Zhang Y, Chen Z, Cheng CH, Thapa R, Thompson Z, Fellows KM, Francis JM, Saller JJ, Mesa T, Zhang C, Yoder S, DeNicola GM, Beg AA, Boyle TA, Teer JK, Ann Chen Y, Koomen JM, Eschrich SA, Haura EB. Proteogenomic landscape of squamous cell lung cancer. Nat Commun. 2019 Aug.10(1):3578. Pubmedid: 31395880. Pmcid: PMC6687710.
  • Creelan BC, Gray JE, Tanvetyanon T, Chiappori AA, Yoshida T, Schell MJ, Antonia SJ, Haura EB. Phase 1 trial of dasatinib combined with afatinib for epidermal growth factor receptor- (EGFR-) mutated lung cancer with acquired tyrosine kinase inhibitor (TKI) resistance. Brit J Cancer. 2019 Apr.120(8):791-796. Pubmedid: 30880334. Pmcid: PMC6474279.
  • Stewart PA, Kuenzi BM, Mehta S, Kumar P, Johnson JE, Jagtap P, Griffin TJ, Haura EB. The Galaxy Platform for Reproducible Affinity Proteomic Mass Spectrometry Data Analysis. Methods Mol Biol. 2019 Apr.1977:249-261. Pubmedid: 30980333. Pmcid: PMC7787333.
  • Yin Q, Han T, Fang B, Zhang G, Zhang C, Roberts ER, Izumi V, Zheng M, Jiang S, Yin X, Kim M, Cai J, Haura EB, Koomen JM, Smalley KSM, Wan L. K27-linked ubiquitination of BRAF by ITCH engages cytokine response to maintain MEK-ERK signaling. Nat Commun. 2019 Apr.10(1):1870. Pubmedid: 31015455. Pmcid: PMC6478693.
  • Farago AF, Taylor MS, Doebele RC, Zhu VW, Kummar S, Spira AI, Boyle TA, Haura EB, Arcila ME, Benayed R, Aisner DL, Horick NK, Lennerz JK, Le LP, Iafrate AJ, Ou SI, Shaw AT, Mino-Kenudson M, Drilon A. Clinicopathologic Features of Non-Small-Cell Lung Cancer Harboring an NTRK Gene Fusion. JCO Precis Oncol. 2018 Sep.2018. Pubmedid: 30215037. Pmcid: PMC6132056.
  • Boutchueng-Djidjou M, Rix U, Haura EB. Bidirectional Adaptive Signaling between cancer and stromal cells: mechanisms and therapeutics. Expert Rev Proteomics. 2018 Sep.15(9):697-699. Pubmedid: 30251554. Pmcid: PMC6435031.
  • Li Y, Xiao X, Han Y, Gorlova O, Qian D, Leighl N, Johansen JS, Barnett M, Chen C, Goodman G, Cox A, Taylor F, Woll P, Wichmann HE, Manz J, Muley T, Risch A, Rosenberger A, Arnold SM, Haura EB, Bolca C, Holcatova I, Janout V, Kontic M, Lissowska J, Mukeria A, Ognjanovic S, Orlowski TM, Scelo G, Swiatkowska B, Zaridze D, Bakke P, Skaug V, Zienolddiny S, Duell EJ, Butler LM, Houlston R, Artigas MS, Grankvist K, Johansson M, Shepherd FA, Marcus MW, Brunnström H, Manjer J, Melander O, Muller DC, Overvad K, Trichopoulou A, Tumino R, Liu G, Bojesen SE, Wu X, Le Marchand L, Albanes D, Bickeböller H, Aldrich MC, Bush WS, Tardon A, Rennert G, Teare MD, Field JK, Kiemeney LA, Lazarus P, Haugen A, Lam S, Schabath MB, Andrew AS, Bertazzi PA, Pesatori AC, Christiani DC, Caporaso N, Johansson M, McKay JD, Brennan P, Hung RJ, Amos CI. Genome-wide interaction study of smoking behavior and non-small cell lung cancer risk in Caucasian population. Carcinogenesis. 2018 Mar.39(3):336-346. Pubmedid: 29059373. Pmcid: PMC6248554.
  • Ramello MC, Haura EB, Abate-Daga D. CAR-T cells and combination therapies: What's next in the immunotherapy revolution?. Pharmacol Res. 2018 Mar.129:194-203. Pubmedid: 29203440. Pmcid: PMC5828987.
  • Aisner DL, Sholl LM, Berry L, Rossi M, Chen H, Fujimoto J, Moreira AL, Ramalingam S, Villaruz LC, Otterson GA, Haura EB, Politi K, Glisson BS, Cetnar J, Garon E, Schiller J, Waqar S, Sequist LV, Brahmer JR, Shyr Y, Kugler K, Wistuba II, Johnson BE, Minna JD, Kris MG, Bunn PA, Kwiatkowski DJ. The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations-The Lung Cancer Mutation Consortium (LCMC2). Clin Cancer Res. 2018 Mar.24(5):1038-1047. Pubmedid: 29217530. Pmcid: PMC7008001.
  • Kim E, Kim JY, Smith MA, Haura EB, Anderson ARA. Cell signaling heterogeneity is modulated by both cell-intrinsic and -extrinsic mechanisms: An integrated approach to understanding targeted therapy. PLoS Biol. 2018 Mar.16(3):e2002930. Pubmedid: 29522507. Pmcid: PMC5844524.
  • Hoffman MA, Fang B, Haura EB, Rix U, Koomen JM. Comparison of Quantitative Mass Spectrometry Platforms for Monitoring Kinase ATP Probe Uptake in Lung Cancer. J Proteome Res. 2018 Jan.17(1):63-75. Pubmedid: 29164889. Pmcid: PMC6021760.
  • Gray JE, Chiappori A, Williams CC, Tanvetyanon T, Haura EB, Creelan BC, Kim J, Boyle TA, Pinder-Schenck M, Khalil F, Altiok S, Devane R, Noyes D, Mediavilla-Varela M, Smilee R, Hopewell EL, Kelley L, Antonia SJ. A phase I/randomized phase II study of GM.CD40L vaccine in combination with CCL21 in patients with advanced lung adenocarcinoma. Cancer Immunol Immun. 2018 Dec.67(12):1853-1862. Pubmedid: 30209589. Pmcid: PMC6244998.
  • Ctortecka C, Palve V, Kuenzi BM, Fang B, Sumi NJ, Izumi V, Novakova S, Kinose F, Remsing Rix LL, Haura EB, Koomen JM, Rix U. Functional Proteomics and Deep Network Interrogation Reveal a Complex Mechanism of Action of Midostaurin in Lung Cancer Cells. Mol Cell Proteomics. 2018 Dec.17(12):2434-2447. Pubmedid: 30217950. Pmcid: PMC6283294.
  • Ji X, Bossé Y, Landi MT, Gui J, Xiao X, Qian D, Joubert P, Lamontagne M, Li Y, Gorlov I, de Biasi M, Han Y, Gorlova O, Hung RJ, Wu X, McKay J, Zong X, Carreras-Torres R, Christiani DC, Caporaso N, Johansson M, Liu G, Bojesen SE, Le Marchand L, Albanes D, Bickeböller H, Aldrich MC, Bush WS, Tardon A, Rennert G, Chen C, Teare MD, Field JK, Kiemeney LA, Lazarus P, Haugen A, Lam S, Schabath MB, Andrew AS, Shen H, Hong YC, Yuan JM, Bertazzi PA, Pesatori AC, Ye Y, Diao N, Su L, Zhang R, Brhane Y, Leighl N, Johansen JS, Mellemgaard A, Saliba W, Haiman C, Wilkens L, Fernandez-Somoano A, Fernandez-Tardon G, van der Heijden EHFM, Kim JH, Dai J, Hu Z, Davies MPA, Marcus MW, Brunnström H, Manjer J, Melander O, Muller DC, Overvad K, Trichopoulou A, Tumino R, Doherty J, Goodman GE, Cox A, Taylor F, Woll P, Brüske I, Manz J, Muley T, Risch A, Rosenberger A, Grankvist K, Johansson M, Shepherd F, Tsao MS, Arnold SM, Haura EB, Bolca C, Holcatova I, Janout V, Kontic M, Lissowska J, Mukeria A, Ognjanovic S, Orlowski TM, Scelo G, Swiatkowska B, Zaridze D, Bakke P, Skaug V, Zienolddiny S, Duell EJ, Butler LM, Koh WP, Gao YT, Houlston R, McLaughlin J, Stevens V, Nickle DC, Obeidat M, Timens W, Zhu B, Song L, Artigas MS, Tobin MD, Wain LV, Gu F, Byun J, Kamal A, Zhu D, Tyndale RF, Wei WQ, Chanock S, Brennan P, Amos CI. Identification of susceptibility pathways for the role of chromosome 15q25.1 in modifying lung cancer risk. Nat Commun. 2018 Aug.9(1):3221. Pubmedid: 30104567. Pmcid: PMC6089967.
  • Meltzer LR, Meade CD, Diaz DB, Carrington MS, Brandon TH, Jacobsen PB, McCaffrey JC, Haura EB, Simmons VN. Development of a Targeted Smoking Relapse-Prevention Intervention for Cancer Patients. J Cancer Educ. 2018 Apr.33(2):440-447. Pubmedid: 27476432. Pmcid: PMC5288399.
  • Quinn G, Pentz RD, Muñoz-Antonia T, Boyle TA, Schabath MB, Pratt C, Shaffer A, Duarte L, Bowman-Curci M, Antonia S, Chiappori A, Creelan B, Gray JE, Williams C, Haura E. Patient, caregiver and physician perspectives on participating in a thoracic rapid tissue donation program. Patient Educ Couns. 2018 Apr.101(4):703-710. Pubmedid: 29195718. Pmcid: PMC5878993.
  • Chen DT, Huang PY, Lin HY, Chiappori AA, Gabrilovich DI, Haura EB, Antonia SJ, Gray JE. A Bayesian pick-the-winner design in a randomized phase II clinical trial. Oncotarget. 2017 Oct.8(51):88376-88385. Pubmedid: 29179442. Pmcid: PMC5687612.
  • Smith MA, Licata T, Lakhani A, Varella-Garcia M, Schildhaus HU, Vuaroqueaux V, Halmos B, Borczuk A, Chen YA, Creelan BC, Boyle TA, Haura EB. MET-GRB2 Signaling-Associated Complexes Correlate with Oncogenic MET Signaling and Sensitivity to MET Kinase Inhibitors. Clin Cancer Res. 2017 Nov.23(22):7084-7096. Pubmedid: 28855353. Pmcid: PMC5833309.
  • Stewart PA, Fang B, Slebos RJ, Zhang G, Borne AL, Fellows K, Teer JK, Chen YA, Welsh E, Eschrich SA, Haura EB, Koomen JM. Relative protein quantification and accessible biology in lung tumor proteomes from four LC-MS/MS discovery platforms. Proteomics. 2017 Mar.17(6). Pubmedid: 28195392. Pmcid: PMC5606153.
  • Carreras-Torres R, Johansson M, Haycock PC, Wade KH, Relton CL, Martin RM, Davey Smith G, Albanes D, Aldrich MC, Andrew A, Arnold SM, Bickeböller H, Bojesen SE, Brunnström H, Manjer J, Brüske I, Caporaso NE, Chen C, Christiani DC, Christian WJ, Doherty JA, Duell EJ, Field JK, Davies MPA, Marcus MW, Goodman GE, Grankvist K, Haugen A, Hong YC, Kiemeney LA, van der Heijden EHFM, Kraft P, Johansson MB, Lam S, Landi MT, Lazarus P, Le Marchand L, Liu G, Melander O, Park SL, Rennert G, Risch A, Haura EB, Scelo G, Zaridze D, Mukeriya A, Savić M, Lissowska J, Swiatkowska B, Janout V, Holcatova I, Mates D, Schabath MB, Shen H, Tardon A, Teare MD, Woll P, Tsao MS, Wu X, Yuan JM, Hung RJ, Amos CI, McKay J, Brennan P. Obesity, metabolic factors and risk of different histological types of lung cancer: A Mendelian randomization study. PLoS One. 2017 Jun.12(6):e0177875. Pubmedid: 28594918. Pmcid: PMC5464539.
  • Tchekmedyian N, Mudad R, Blanco FF, Raymond VM, Garst J, Erlander MG, Haura E, Berz D. Longitudinal monitoring of ctDNA EGFR mutation burden from urine correlates with patient response to EGFR TKIs: A case series. Lung Cancer. 2017 Jun.108:22-28. Pubmedid: 28625639.
  • Vaishnavi A, Schubert L, Rix U, Marek LA, Le AT, Keysar S, Glogowska MJ, Smith MA, Kako SL, Sumi NJ, Davies KD, Ware KE, Varella-Garcia M, Haura EB, Jimeno A, Heasley LE, Aisner DL, Doebele RC. EGFR Mediates Responses to Small-Molecule Drugs Targeting Oncogenic Fusion Kinases. Cancer Res. 2017 Jul.77(13):3551-3563. Pubmedid: 28428274. Pmcid: PMC5516930.
  • McKay JD, Hung RJ, Han Y, Zong X, Carreras-Torres R, Christiani DC, Caporaso NE, Johansson M, Xiao X, Li Y, Byun J, Dunning A, Pooley KA, Qian DC, Ji X, Liu G, Timofeeva MN, Bojesen SE, Wu X, Le Marchand L, Albanes D, Bickeböller H, Aldrich MC, Bush WS, Tardon A, Rennert G, Teare MD, Field JK, Kiemeney LA, Lazarus P, Haugen A, Lam S, Schabath MB, Andrew AS, Shen H, Hong YC, Yuan JM, Bertazzi PA, Pesatori AC, Ye Y, Diao N, Su L, Zhang R, Brhane Y, Leighl N, Johansen JS, Mellemgaard A, Saliba W, Haiman CA, Wilkens LR, Fernandez-Somoano A, Fernandez-Tardon G, van der Heijden HFM, Kim JH, Dai J, Hu Z, Davies MPA, Marcus MW, Brunnström H, Manjer J, Melander O, Muller DC, Overvad K, Trichopoulou A, Tumino R, Doherty JA, Barnett MP, Chen C, Goodman GE, Cox A, Taylor F, Woll P, Brüske I, Wichmann HE, Manz J, Muley TR, Risch A, Rosenberger A, Grankvist K, Johansson M, Shepherd FA, Tsao MS, Arnold SM, Haura EB, Bolca C, Holcatova I, Janout V, Kontic M, Lissowska J, Mukeria A, Ognjanovic S, Orlowski TM, Scelo G, Swiatkowska B, Zaridze D, Bakke P, Skaug V, Zienolddiny S, Duell EJ, Butler LM, Koh WP, Gao YT, Houlston RS, McLaughlin J, Stevens VL, Joubert P, Lamontagne M, Nickle DC, Obeidat M, Timens W, Zhu B, Song L, Kachuri L, Artigas MS, Tobin MD, Wain LV, Rafnar T, Thorgeirsson TE, Reginsson GW, Stefansson K, Hancock DB, Bierut LJ, Spitz MR, Gaddis NC, Lutz SM, Gu F, Johnson EO, Kamal A, Pikielny C, Zhu D, Lindströem S, Jiang X, Tyndale RF, Chenevix-Trench G, Beesley J, Bossé Y, C ...
  • Gemmill RM, Nasarre P, Nair-Menon J, Cappuzzo F, Landi L, D'Incecco A, Uramoto H, Yoshida T, Haura EB, Armeson K, Drabkin HA. The neuropilin 2 isoform NRP2b uniquely supports TGFβ-mediated progression in lung cancer. Sci Signal. 2017 Jan.10(462). Pubmedid: 28096505. Pmcid: PMC5969810.
  • Gao B, Huang C, Kernstine K, Pelekanou V, Kluger Y, Jiang T, Peters-Hall JR, Coquelin M, Girard L, Zhang W, Huffman K, Oliver D, Kinose F, Haura E, Teer JK, Rix U, Le AT, Aisner DL, Varella-Garcia M, Doebele RC, Covington KR, Hampton OA, Doddapaneni HV, Jayaseelan JC, Hu J, Wheeler DA, Shay JW, Rimm DL, Gazdar A, Minna JD. Non-malignant respiratory epithelial cells preferentially proliferate from resected non-small cell lung cancer specimens cultured under conditionally reprogrammed conditions. Oncotarget. 2017 Feb.8(7):11114-11126. Pubmedid: 28052041. Pmcid: PMC5355251.
  • Lohavanichbutr P, Sakoda LC, Amos CI, Arnold SM, Christiani DC, Davies MPA, Field JK, Haura EB, Hung RJ, Kohno T, Landi MT, Liu G, Liu Y, Marcus MW, O'Kane GM, Schabath MB, Shiraishi K, Slone SA, Tardon A, Yang P, Yoshida K, Zhang R, Zong X, Goodman GG, Weiss NS, Chen C. Common Polymorphisms in Relation to Survival among Small Cell Lung Cancer Patients: A Multicenter Study from the International Lung Cancer Consortium. Clin Cancer Res. 2017 Dec.23(24):7550-7557. Pubmedid: 28974547. Pmcid: PMC5732876.
  • Kuenzi BM, Remsing Rix LL, Stewart PA, Fang B, Kinose F, Bryant AT, Boyle TA, Koomen JM, Haura EB, Rix U. Polypharmacology-based ceritinib repurposing using integrated functional proteomics. Nat Chem Biol. 2017 Dec.13(12):1222-1231. Pubmedid: 28991240. Pmcid: PMC5909815.
  • Cohen AS, Khalil FK, Welsh EA, Schabath MB, Enkemann SA, Davis A, Zhou JM, Boulware DC, Kim J, Haura EB, Morse DL. Cell-surface marker discovery for lung cancer. Oncotarget. 2017 Dec.8(69):113373-113402. Pubmedid: 29371917. Pmcid: PMC5768334.
  • Creelan BC, Gabrilovich DI, Gray JE, Williams CC, Tanvetyanon T, Haura EB, Weber JS, Gibney GT, Markowitz J, Proksch JW, Reisman SA, McKee MD, Chin MP, Meyer CJ, Antonia SJ. Safety, pharmacokinetics, and pharmacodynamics of oral omaveloxolone (RTA 408), a synthetic triterpenoid, in a first-in-human trial of patients with advanced solid tumors. Onco Targets Ther. 2017 Aug.10:4239-4250. Pubmedid: 28919776. Pmcid: PMC5587199.
  • Dhawan A, Nichol D, Kinose F, Abazeed ME, Marusyk A, Haura EB, Scott JG. Collateral sensitivity networks reveal evolutionary instability and novel treatment strategies in ALK mutated non-small cell lung cancer. Sci Rep. 2017 Apr.7(1):1232. Pubmedid: 28450729. Pmcid: PMC5430816.
  • Díaz DB, Brandon TH, Sutton SK, Meltzer LR, Hoehn HJ, Meade CD, Jacobsen PB, McCaffrey JC, Haura EB, Lin HY, Simmons VN. Smoking relapse-prevention intervention for cancer patients: Study design and baseline data from the surviving SmokeFree randomized controlled trial. Contemp Clin Trials. 2016 Sep.50:84-89. Pubmedid: 27468664. Pmcid: PMC5564185.
  • Kim JY, Welsh EA, Fang B, Bai Y, Kinose F, Eschrich SA, Koomen JM, Haura EB. Phosphoproteomics Reveals MAPK Inhibitors Enhance MET- and EGFR-Driven AKT Signaling in KRAS-Mutant Lung Cancer. Mol Cancer Res. 2016 Oct.14(10):1019-1029. Pubmedid: 27422710. Pmcid: PMC5065770.
  • Huang Q, Schneeberger VE, Luetteke N, Jin C, Afzal R, Budzevich MM, Makanji RJ, Martinez GV, Shen T, Zhao L, Fung KM, Haura EB, Coppola D, Wu J. Preclinical Modeling of KIF5B-RET Fusion Lung Adenocarcinoma. Mol Cancer Ther. 2016 Oct.15(10):2521-2529. Pubmedid: 27496134. Pmcid: PMC5289739.
  • Halmos B, Haura EB. New twists in the AXL(e) of tumor progression. Sci Signal. 2016 Oct.9(448):fs14. Pubmedid: 27703029.
  • Zhang G, Scarborough H, Kim J, Rozhok AI, Chen YA, Zhang X, Song L, Bai Y, Fang B, Liu RZ, Koomen J, Tan AC, Degregori J, Haura EB. Coupling an EML4-ALK-centric interactome with RNA interference identifies sensitizers to ALK inhibitors. Sci Signal. 2016 Oct.9(450):rs12. Pubmedid: 27811184. Pmcid: PMC5377910.
  • Haake SM, Li J, Bai Y, Kinose F, Fang B, Welsh EA, Zent R, Dhillon J, Pow-Sang JM, Chen YA, Koomen JM, Rathmell WK, Fishman M, Haura EB. Tyrosine Kinase Signaling in Clear Cell and Papillary Renal Cell Carcinoma Revealed by Mass Spectrometry-Based Phosphotyrosine Proteomics. Clin Cancer Res. 2016 Nov.22(22):5605-5616. Pubmedid: 27220961. Pmcid: PMC5122466.
  • Haake SM, Brooks SA, Welsh E, Fulp WJ, Chen DT, Dhillon J, Haura E, Sexton W, Spiess PE, Pow-Sang J, Rathmell WK, Fishman M. Patients with ClearCode34-identified molecular subtypes of clear cell renal cell carcinoma represent unique populations with distinct comorbidities. Urol Oncol. 2016 Mar.34(3):122.e1-122.e7. Pubmedid: 26546482. Pmcid: PMC4761468.
  • Schabath MB, Welsh EA, Fulp WJ, Chen L, Teer JK, Thompson ZJ, Engel BE, Xie M, Berglund AE, Creelan BC, Antonia SJ, Gray JE, Eschrich SA, Chen DT, Cress WD, Haura EB, Beg AA. Differential association of STK11 and TP53 with KRAS mutation-associated gene expression, proliferation and immune surveillance in lung adenocarcinoma. Oncogene. 2016 Jun.35(24):3209-3216. Pubmedid: 26477306. Pmcid: PMC4837098.
  • Chen L, Engel BE, Welsh EA, Yoder SJ, Brantley SG, Chen DT, Beg AA, Cao C, Kaye FJ, Haura EB, Schabath MB, Cress WD. A Sensitive NanoString-Based Assay to Score STK11 (LKB1) Pathway Disruption in Lung Adenocarcinoma. J Thorac Oncol. 2016 Jun.11(6):838-849. Pubmedid: 26917230. Pmcid: PMC4877210.
  • Chen Z, Li JL, Lin S, Cao C, Gimbrone NT, Yang R, Fu DA, Carper MB, Haura EB, Schabath MB, Lu J, Amelio AL, Cress WD, Kaye FJ, Wu L. cAMP/CREB-regulated LINC00473 marks LKB1-inactivated lung cancer and mediates tumor growth. J Clin Invest. 2016 Jun.126(6):2267-2279. Pubmedid: 27140397. Pmcid: PMC4887185.
  • Kim JY, Stewart PA, Borne AL, Fang B, Welsh EA, Chen YA, Eschrich SA, Koomen JM, Haura EB. Activity-Based Proteomics Reveals Heterogeneous Kinome and ATP-Binding Proteome Responses to MEK Inhibition in KRAS Mutant Lung Cancer. Proteomes. 2016 Jun.4(2):16. Pubmedid: 28154798. Pmcid: PMC5217344.
  • Tchekmedyian N, Ali SM, Miller VA, Haura EB. Acquired ALK L1152R Mutation Confers Resistance to Ceritinib and Predicts Response to Alectinib. J Thorac Oncol. 2016 Jul.11(7):e87-e88. Pubmedid: 27091190.
  • Jhuraney A, Woods NT, Wright G, Rix L, Kinose F, Kroeger JL, Remily-Wood E, Cress WD, Koomen JM, Brantley SG, Gray JE, Haura EB, Rix U, Monteiro AN. PAXIP1 Potentiates the Combination of WEE1 Inhibitor AZD1775 and Platinum Agents in Lung Cancer. Mol Cancer Ther. 2016 Jul.15(7):1669-1681. Pubmedid: 27196765. Pmcid: PMC4936941.
  • Yoshida T, Song L, Bai Y, Kinose F, Li J, Ohaegbulam KC, Muñoz-Antonia T, Qu X, Eschrich S, Uramoto H, Tanaka F, Nasarre P, Gemmill RM, Roche J, Drabkin HA, Haura EB. ZEB1 Mediates Acquired Resistance to the Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer. PLoS One. 2016 Jan.11(1):e0147344. Pubmedid: 26789630. Pmcid: PMC4720447.
  • Li J, Fang B, Kinose F, Bai Y, Kim JY, Chen YA, Rix U, Koomen JM, Haura EB. Target Identification in Small Cell Lung Cancer via Integrated Phenotypic Screening and Activity-Based Protein Profiling. Mol Cancer Ther. 2016 Feb.15(2):334-342. Pubmedid: 26772203. Pmcid: PMC4747823.
  • Chen DT, Huang PY, Lin HY, Haura EB, Antonia SJ, Cress WD, Gray JE. Strategies for power calculations in predictive biomarker studies in survival data. Oncotarget. 2016 Dec.7(49):80373-80381. Pubmedid: 27661007. Pmcid: PMC5348326.
  • Kuenzi BM, Borne AL, Li J, Haura EB, Eschrich SA, Koomen JM, Rix U, Stewart PA. APOSTL: An Interactive Galaxy Pipeline for Reproducible Analysis of Affinity Proteomics Data. J Proteome Res. 2016 Dec.15(12):4747-4754. Pubmedid: 27680298. Pmcid: PMC5231908.
  • Chen L, Kurtyka CA, Welsh EA, Rivera JI, Engel BE, Muñoz-Antonia T, Yoder SJ, Eschrich SA, Creelan BC, Chiappori AA, Gray JE, Ramirez JL, Rosell R, Schabath MB, Haura EB, Chen DT, Cress WD. Early2 factor (E2F) deregulation is a prognostic and predictive biomarker in lung adenocarcinoma. Oncotarget. 2016 Dec.7(50):82254-82265. Pubmedid: 27756884. Pmcid: PMC5347689.
  • Knezevic CE, Wright G, Remsing Rix LL, Kim W, Kuenzi BM, Luo Y, Watters JM, Koomen JM, Haura EB, Monteiro AN, Radu C, Lawrence HR, Rix U. Proteome-wide Profiling of Clinical PARP Inhibitors Reveals Compound-Specific Secondary Targets. Cell Chem Biol. 2016 Dec.23(12):1490-1503. Pubmedid: 27866910. Pmcid: PMC5182133.
  • Smida M, Fece de la Cruz F, Kerzendorfer C, Uras IZ, Mair B, Mazouzi A, Suchankova T, Konopka T, Katz AM, Paz K, Nagy-Bojarszky K, Muellner MK, Bago-Horvath Z, Haura EB, Loizou JI, Nijman SM. MEK inhibitors block growth of lung tumours with mutations in ataxia-telangiectasia mutated. Nat Commun. 2016 Dec.7:13701. Pubmedid: 27922010. Pmcid: PMC5150652.
  • Zheng H, Zhao W, Yan C, Watson CC, Messengill M, Xie M, Messengill C, Noyes D, Martinez GV, Afzal R, Chen Z, Ren X, Antonia SJ, Haura EB, Ruffell B, Beg AA. HDAC Inhibitors Enhance T-Cell Chemokine Expression and Augment Response to PD-1 Immunotherapy in Lung Adenocarcinoma. Clin Cancer Res. 2016 Aug.22(16):4119-4132. Pubmedid: 26964571. Pmcid: PMC4987196.
  • Challa S, Guo J, Ding X, Xu CX, Li Y, Kim D, Smith MA, Cress WD, Coppola D, Haura EB, Cheng JQ. IKBKE Is a Substrate of EGFR and a Therapeutic Target in Non-Small Cell Lung Cancer with Activating Mutations of EGFR. Cancer Res. 2016 Aug.76(15):4418-4429. Pubmedid: 27287717. Pmcid: PMC4970891.
  • Hudson J, Munoz-Antonia T, Haura E, Cress D, Simmons VN, Quinn GP. Translating Hispanic Genomic Factors in Lung Cancer Into Clinical Practice: EGFR Testing for Improved Outcomes. Gene Cell Tissue. 2016 Apr.3(2). Pubmedid: 29888762. Pmcid: PMC5990038.
  • Baldelli E, Haura EB, Crinò L, Cress WD, Ludovini V, Schabath MB, Liotta LA, Petricoin EF, Pierobon M. Impact of upfront cellular enrichment by laser capture microdissection on protein and phosphoprotein drug target signaling activation measurements in human lung cancer: Implications for personalized medicine. Proteom Clin Appl. 2015 Oct.9(9-10):928-937. Pubmedid: 25676683. Pmcid: PMC4547918.
  • Baldelli E, Bellezza G, Haura EB, Crinó L, Cress WD, Deng J, Ludovini V, Sidoni A, Schabath MB, Puma F, Vannucci J, Siggillino A, Liotta LA, Petricoin EF, Pierobon M. Functional signaling pathway analysis of lung adenocarcinomas identifies novel therapeutic targets for KRAS mutant tumors. Oncotarget. 2015 Oct.6(32):32368-32379. Pubmedid: 26468985. Pmcid: PMC4741699.
  • Stewart PA, Parapatics K, Welsh EA, Müller AC, Cao H, Fang B, Koomen JM, Eschrich SA, Bennett KL, Haura EB. A Pilot Proteogenomic Study with Data Integration Identifies MCT1 and GLUT1 as Prognostic Markers in Lung Adenocarcinoma. PLoS One. 2015 Nov.10(11):e0142162. Pubmedid: 26539827. Pmcid: PMC4634858.
  • Chellappan SP, Pillai S, Trevino JG, Rawal B, Singh S, Kovacs M, Li X, Schell MJ, Haura EB, Bepler G. β-arrestin-1 mediates nicotine-induced metastasis through E2F1 target genes that modulate epithelial-mesenchymal transition. Cancer Res. 2015 Mar.75(6):1009-1020. Pubmedid: 25600647. Pmcid: PMC4359962.
  • Schneeberger VE, Ren Y, Luetteke N, Huang Q, Chen L, Lawrence HR, Lawrence NJ, Haura EB, Koomen JM, Coppola D, Wu J. Inhibition of Shp2 suppresses mutant EGFR-induced lung tumors in transgenic mouse model of lung adenocarcinoma. Oncotarget. 2015 Mar.6(8):6191-6202. Pubmedid: 25730908. Pmcid: PMC4467431.
  • Woods NT, Monteiro AN, Thompson ZJ, Amankwah EK, Naas N, Haura EB, Beg AA, Schabath MB. Interleukin polymorphisms associated with overall survival, disease-free survival, and recurrence in non-small cell lung cancer patients. Mol Carcinogen. 2015 Jun.54 Suppl 1:E172-E184. Pubmedid: 25597281. Pmcid: PMC4475444.
  • Fang B, Hoffman MA, Mirza AS, Mishall KM, Li J, Peterman SM, Smalley KS, Shain KH, Weinberger PM, Wu J, Rix U, Haura EB, Koomen JM. Evaluating kinase ATP uptake and tyrosine phosphorylation using multiplexed quantification of chemically labeled and post-translationally modified peptides. Methods. 2015 Jun.81:41-49. Pubmedid: 25782629. Pmcid: PMC4460980.
  • Haura EB, Beg AA, Rix U, Antonia S. Charting Immune Signaling Proteomes En Route to New Therapeutic Strategies. Cancer Immunol Res. 2015 Jul.3(7):714-720. Pubmedid: 26081226. Pmcid: PMC4491034.
  • Cao C, Gao R, Zhang M, Amelio AL, Fallahi M, Chen Z, Gu Y, Hu C, Welsh EA, Engel BE, Haura EB, Cress WD, Wu L, Zajac-Kaye M, Kaye FJ. Role of LKB1-CRTC1 on glycosylated COX-2 and response to COX-2 inhibition in lung cancer. J Natl Cancer Inst. 2015 Jan.107(1):358. Pubmedid: 25465874. Pmcid: PMC4271078.
  • Smith MA, Hall R, Fisher K, Haake SM, Khalil F, Schabath MB, Vuaroqueaux V, Fiebig HH, Altiok S, Chen YA, Haura EB. Annotation of human cancers with EGFR signaling-associated protein complexes using proximity ligation assays. Sci Signal. 2015 Jan.8(359):ra4. Pubmedid: 25587191. Pmcid: PMC4440040.
  • Villaruz LC, Socinski MA, Abberbock S, Berry LD, Johnson BE, Kwiatkowski DJ, Iafrate AJ, Varella-Garcia M, Franklin WA, Camidge DR, Sequist LV, Haura EB, Ladanyi M, Kurland BF, Kugler K, Minna JD, Bunn PA, Kris MG. Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium. Cancer. 2015 Feb.121(3):448-456. Pubmedid: 25273224. Pmcid: PMC4305000.
  • Pillai S, Nguyen J, Johnson J, Haura E, Coppola D, Chellappan S. Tank binding kinase 1 is a centrosome-associated kinase necessary for microtubule dynamics and mitosis. Nat Commun. 2015 Dec.6:10072. Pubmedid: 26656453. Pmcid: PMC4682058.
  • Haura EB, Rix U. Deploying ibrutinib to lung cancer: another step in the quest towards drug repurposing. J Natl Cancer Inst. 2014 Sep.106(9). Pubmedid: 25214562. Pmcid: PMC5072366.
  • Kumar NB, Quinn GP, Alexandrow MG, Gray J, Schell M, Sutton S, Haura EB. Chemoprevention Trial Feasibility Using Botanicals in Exceptionally High Risk Populations for Lung Cancer. J Clin Trials. 2014 Sep.4(4). Pubmedid: 26101725. Pmcid: PMC4474484.
  • Gridling M, Ficarro S, Breitwieser FP, Song L, Parapatics K, Colinge J, Haura EB, Marto J, Superti-Furga G, Bennett KL, Rix U. Identification of kinase inhibitor targets in the lung cancer microenvironment by chemical and phosphoproteomics. Mol Cancer Ther. 2014 Nov.13(11):2751-2762. Pubmedid: 25189542. Pmcid: PMC4221415.
  • Dilling TJ, Extermann M, Kim J, Thompson LM, Yue B, Stevens CW, Antonia S, Gray J, Williams C, Haura E, Pinder-Schenck M, Tanvetyanon T, Kim S, Chiappori A. Phase 2 study of concurrent cetuximab plus definitive thoracic radiation therapy followed by consolidation docetaxel plus cetuximab in poor prognosis or elderly patients with locally advanced non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2014 Nov.90(4):828-833. Pubmedid: 25216856.
  • Kris MG, Johnson BE, Berry LD, Kwiatkowski DJ, Iafrate AJ, Wistuba II, Varella-Garcia M, Franklin WA, Aronson SL, Su PF, Shyr Y, Camidge DR, Sequist LV, Glisson BS, Khuri FR, Garon EB, Pao W, Rudin C, Schiller J, Haura EB, Socinski M, Shirai K, Chen H, Giaccone G, Ladanyi M, Kugler K, Minna JD, Bunn PA. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. Jama. 2014 May.311(19):1998-2006. Pubmedid: 24846037. Pmcid: PMC4163053.
  • Gray J, Haura EB, Chiappori A, Tanvetyanon T, Williams CC, Pinder-Schenk M, Kish JA, Kreahling JM, Lush RM, Neuger AM, Tetteh LF, Akar A, Zhao X, Schell MJ, Bepler G, Altiok S. A phase I, pharmacokinetic, and pharmacodynamic study of panobinostat, an HDAC inhibitor, combined with erlotinib in patients with advanced aerodigestive tract tumors. Clin Cancer Res. 2014 Mar.20(6):1644-1655. Pubmedid: 24429877. Pmcid: PMC4051132.
  • Donatelli SS, Zhou JM, Gilvary DL, Eksioglu EA, Chen X, Cress WD, Haura EB, Schabath MB, Coppola D, Wei S, Djeu JY. TGF-β-inducible microRNA-183 silences tumor-associated natural killer cells. Proc Natl Acad Sci U S A. 2014 Mar.111(11):4203-4208. Pubmedid: 24586048. Pmcid: PMC3964044.
  • Song L, Smith MA, Doshi P, Sasser K, Fulp W, Altiok S, Haura EB. Antitumor efficacy of the anti-interleukin-6 (IL-6) antibody siltuximab in mouse xenograft models of lung cancer. J Thorac Oncol. 2014 Jul.9(7):974-982. Pubmedid: 24922005. Pmcid: PMC4057975.
  • Chiappori A, Williams C, Northfelt DW, Adams JW, Malik S, Edelman MJ, Rosen P, Van Echo DA, Berger MS, Haura EB. Obatoclax mesylate, a pan-bcl-2 inhibitor, in combination with docetaxel in a phase 1/2 trial in relapsed non-small-cell lung cancer. J Thorac Oncol. 2014 Jan.9(1):121-125. Pubmedid: 24346101. Pmcid: PMC4666503.
  • Schabath MB, McIntyre J, Pratt C, Gonzalez LE, Munoz-Antonia T, Haura EB, Quinn GP. Healthcare providers' knowledge and attitudes about rapid tissue donation (RTD): phase one of establishing a rapid tissue donation programme in thoracic oncology. J Med Ethics. 2014 Feb.40(2):139-142. Pubmedid: 23557908. Pmcid: PMC3924895.
  • Remsing Rix LL, Kuenzi BM, Luo Y, Remily-Wood E, Kinose F, Wright G, Li J, Koomen JM, Haura EB, Lawrence HR, Rix U. GSK3 alpha and beta are new functionally relevant targets of tivantinib in lung cancer cells. Acs Chem Biol. 2014 Feb.9(2):353-358. Pubmedid: 24215125. Pmcid: PMC3944088.
  • Bai Y, Kim JY, Watters JM, Fang B, Kinose F, Song L, Koomen JM, Teer JK, Fisher K, Chen YA, Rix U, Haura EB. Adaptive responses to dasatinib-treated lung squamous cell cancer cells harboring DDR2 mutations. Cancer Res. 2014 Dec.74(24):7217-7228. Pubmedid: 25348954. Pmcid: PMC4326029.
  • Gordian E, Li J, Pevzner Y, Mediavilla-Varela M, Luddy K, Ohaegbulam K, Daniel KG, Haura EB, Muñoz-Antonia T. Transforming growth factor β signaling overcomes dasatinib resistance in lung cancer. PLoS One. 2014 Dec.9(12):e114131. Pubmedid: 25501935. Pmcid: PMC4263601.
  • Gray J, Haura E. Update on third-generation EGFR tyrosine kinase inhibitors. Transl Lung Cancer Res. 2014 Dec.3(6):360-362. Pubmedid: 25806319. Pmcid: PMC4367680.
  • Schneeberger VE, Luetteke N, Ren Y, Berns H, Chen L, Foroutan P, Martinez GV, Haura EB, Chen J, Coppola D, Wu J. SHP2E76K mutant promotes lung tumorigenesis in transgenic mice. Carcinogenesis. 2014 Aug.35(8):1717-1725. Pubmedid: 24480804. Pmcid: PMC4123642.
  • Yoshida T, Zhang G, Smith MA, Lopez AS, Bai Y, Li J, Fang B, Koomen JM, Rawal B, Fisher KJ, Chen YA, Kitano M, Morita Y, Yamaguchi H, Shibata K, Okabe T, Okamoto I, Nakagawa K, Haura EB. Tyrosine phosphoproteomics identifies both codrivers and cotargeting strategies for T790M-related EGFR-TKI resistance in non-small cell lung cancer. Clin Cancer Res. 2014 Aug.20(15):4059-4074. Pubmedid: 24919575. Pmcid: PMC4119578.
  • Quinn GP, Haura EB, Murphy D. The ethical imperative of risk disclosure in research: the answer is always yes. Am J Bioethics. 2014.14(4):18-19. Pubmedid: 24730484.
  • Chamrád I, Rix U, Stukalov A, Gridling M, Parapatics K, Müller AC, Altiok S, Colinge J, Superti-Furga G, Haura EB, Bennett KL. A miniaturized chemical proteomic approach for target profiling of clinical kinase inhibitors in tumor biopsies. J Proteome Res. 2013 Sep.12(9):4005-4017. Pubmedid: 23901793. Pmcid: PMC4127982.
  • Kim JY, Beg AA, Haura EB. Non-canonical IKKs, IKKϵ and TBK1, as novel therapeutic targets in the treatment of non-small cell lung cancer. Expert Opin Ther Targets. 2013 Oct.17(10):1109-1112. Pubmedid: 23984985.
  • Creelan BC, Antonia S, Noyes D, Hunter TB, Simon GR, Bepler G, Williams CC, Tanvetyanon T, Haura EB, Schell MJ, Chiappori A. Phase II trial of a GM-CSF-producing and CD40L-expressing bystander cell line combined with an allogeneic tumor cell-based vaccine for refractory lung adenocarcinoma. J Immunother. 2013 Oct.36(8):442-450. Pubmedid: 23994887. Pmcid: PMC3846277.
  • Quinn GP, Murphy D, Pratt C, Muñoz-Antonia T, Guerra L, Schabath MB, Leon ME, Haura E. Altruism in terminal cancer patients and rapid tissue donation program: does the theory apply?. Med Health Care Phil. 2013 Nov.16(4):857-864. Pubmedid: 23539332. Pmcid: PMC3735793.
  • Schabath MB, Giuliano AR, Thompson ZJ, Amankwah EK, Gray J, Fenstermacher DA, Jonathan KA, Beg AA, Haura EB. TNFRSF10B polymorphisms and haplotypes associated with increased risk of death in non-small cell lung cancer. Carcinogenesis. 2013 Nov.34(11):2525-2530. Pubmedid: 23839018. Pmcid: PMC3810840.
  • Williams KA, Zhang M, Xiang S, Hu C, Wu JY, Zhang S, Ryan M, Cox AD, Der CJ, Fang B, Koomen J, Haura E, Bepler G, Nicosia SV, Matthias P, Wang C, Bai W, Zhang X. Extracellular signal-regulated kinase (ERK) phosphorylates histone deacetylase 6 (HDAC6) at serine 1035 to stimulate cell migration. J Biol Chem. 2013 Nov.288(46):33156-33170. Pubmedid: 24089523. Pmcid: PMC3829163.
  • Haura EB, Smith MA. Signaling control by epidermal growth factor receptor and MET: rationale for cotargeting strategies in lung cancer. J Clin Oncol. 2013 Nov.31(32):4148-4150. Pubmedid: 24101046.
  • Li J, Bennett K, Stukalov A, Fang B, Zhang G, Yoshida T, Okamoto I, Kim JY, Song L, Bai Y, Qian X, Rawal B, Schell M, Grebien F, Winter G, Rix U, Eschrich S, Colinge J, Koomen J, Superti-Furga G, Haura EB. Perturbation of the mutated EGFR interactome identifies vulnerabilities and resistance mechanisms. Mol Syst Biol. 2013 Nov.9:705. Pubmedid: 24189400. Pmcid: PMC4039310.
  • Hopewell EL, Zhao W, Fulp WJ, Bronk CC, Lopez AS, Massengill M, Antonia S, Celis E, Haura EB, Enkemann SA, Chen DT, Beg AA. Lung tumor NF-κB signaling promotes T cell-mediated immune surveillance. J Clin Invest. 2013 Jun.123(6):2509-2522. Pubmedid: 23635779. Pmcid: PMC3668836.
  • Bepler G, Williams C, Schell MJ, Chen W, Zheng Z, Simon G, Gadgeel S, Zhao X, Schreiber F, Brahmer J, Chiappori A, Tanvetyanon T, Pinder-Schenck M, Gray J, Haura E, Antonia S, Fischer JR. Randomized international phase III trial of ERCC1 and RRM1 expression-based chemotherapy versus gemcitabine/carboplatin in advanced non-small-cell lung cancer. J Clin Oncol. 2013 Jul.31(19):2404-2412. Pubmedid: 23690416. Pmcid: PMC3691357.
  • Song T, Yang L, Kabra N, Chen L, Koomen J, Haura EB, Chen J. The NAD+ synthesis enzyme nicotinamide mononucleotide adenylyltransferase (NMNAT1) regulates ribosomal RNA transcription. J Biol Chem. 2013 Jul.288(29):20908-20917. Pubmedid: 23737528. Pmcid: PMC3774361.
  • Kim JY, Welsh EA, Oguz U, Fang B, Bai Y, Kinose F, Bronk C, Remsing Rix LL, Beg AA, Rix U, Eschrich SA, Koomen JM, Haura EB. Dissection of TBK1 signaling via phosphoproteomics in lung cancer cells. Proc Natl Acad Sci U S A. 2013 Jul.110(30):12414-12419. Pubmedid: 23836654. Pmcid: PMC3725062.
  • Guo J, Kim D, Gao J, Kurtyka C, Chen H, Yu C, Wu D, Mittal A, Beg AA, Chellappan SP, Haura EB, Cheng JQ. IKBKE is induced by STAT3 and tobacco carcinogen and determines chemosensitivity in non-small cell lung cancer. Oncogene. 2013 Jan.32(2):151-159. Pubmedid: 22330135. Pmcid: PMC4109158.
  • McIntyre J, Pratt C, Pentz RD, Haura EB, Quinn GP. Stakeholder perceptions of thoracic rapid tissue donation: An exploratory study. Soc Sci Med. 2013 Dec.99:35-41. Pubmedid: 24355468. Pmcid: PMC3869974.
  • Alexandrow MG, Song LJ, Altiok S, Gray J, Haura EB, Kumar NB. Curcumin: a novel Stat3 pathway inhibitor for chemoprevention of lung cancer. Eur J Cancer Prev. 2012 Sep.21(5):407-412. Pubmedid: 22156994. Pmcid: PMC3319490.
  • Singh S, Trevino J, Bora-Singhal N, Coppola D, Haura E, Altiok S, Chellappan SP. EGFR/Src/Akt signaling modulates Sox2 expression and self-renewal of stem-like side-population cells in non-small cell lung cancer. Mol Cancer. 2012 Sep.11:73. Pubmedid: 23009336. Pmcid: PMC3497614.
  • Chen L, Chen DT, Kurtyka C, Rawal B, Fulp WJ, Haura EB, Cress WD. Tripartite motif containing 28 (Trim28) can regulate cell proliferation by bridging HDAC1/E2F interactions. J Biol Chem. 2012 Nov.287(48):40106-40118. Pubmedid: 23060449. Pmcid: PMC3504725.
  • Simon GR, Schell MJ, Begum M, Kim J, Chiappori A, Haura E, Antonia S, Bepler G. Preliminary indication of survival benefit from ERCC1 and RRM1-tailored chemotherapy in patients with advanced nonsmall cell lung cancer: evidence from an individual patient analysis. Cancer. 2012 May.118(9):2525-2531. Pubmedid: 22028294. Pmcid: PMC3270127.
  • Bai Y, Li J, Fang B, Edwards A, Zhang G, Bui M, Eschrich S, Altiok S, Koomen J, Haura EB. Phosphoproteomics identifies driver tyrosine kinases in sarcoma cell lines and tumors. Cancer Res. 2012 May.72(10):2501-2511. Pubmedid: 22461510. Pmcid: PMC4641440.
  • Haura EB, Sacco R, Li J, Müller AC, Grebien F, Superti-Furga G, Bennett KL. Optimisation of Downscaled Tandem Affinity Purifications to Identify Core Protein Complexes. J Integr OMICS. 2012 May.2(1):55-68. Pubmedid: 24077984. Pmcid: PMC3785125.
  • Li R, Martin MP, Liu Y, Wang B, Patel RA, Zhu JY, Sun N, Pireddu R, Lawrence NJ, Li J, Haura EB, Sung SS, Guida WC, Schonbrunn E, Sebti SM. Fragment-based and structure-guided discovery and optimization of Rho kinase inhibitors. J Med Chem. 2012 Mar.55(5):2474-2478. Pubmedid: 22272748. Pmcid: PMC4516226.
  • Xiong H, Lee RJ, Haura EB, Edwards JG, Dynan WS, Li S. Intranuclear delivery of a novel antibody-derived radiosensitizer targeting the DNA-dependent protein kinase catalytic subunit. Int J Radiat Oncol Biol Phys. 2012 Jul.83(3):1023-1030. Pubmedid: 22138455. Pmcid: PMC3698569.
  • McBride A, Antonia SJ, Haura EB, Goetz D. Suspected methotrexate toxicity from omeprazole: a case review of carboxypeptidase G2 use in a methotrexate-experienced patient with methotrexate toxicity and a review of the literature. J Pharm Pract. 2012 Aug.25(4):477-485. Pubmedid: 22550162.
  • Haura EB. From modules to medicine: How modular domains and their associated networks can enable personalized medicine. FEBS Lett. 2012 Aug.586(17):2580-2585. Pubmedid: 22575759. Pmcid: PMC4084654.
  • Yoshida T, Haura EB. The potential benefits of BIM in the further pursuit of biomarker discovery in cancer therapeutics. Cancer Discov. 2011 Sep.1(4):289-290. Pubmedid: 22586609.
  • Simon GR, Ilaria RL, Sovak MA, Williams CC, Haura EB, Cleverly AL, Sykes AK, Wagner MM, de Alwis DP, Slapak CA, Miller MA, Spriggs DR. A phase I study of tasisulam sodium (LY573636 sodium), a novel anticancer compound in patients with refractory solid tumors. Cancer Chemother Pharmacol. 2011 Nov.68(5):1233-1241. Pubmedid: 21431416. Pmcid: PMC3215883.
  • Song L, Rawal B, Nemeth JA, Haura EB. JAK1 activates STAT3 activity in non-small-cell lung cancer cells and IL-6 neutralizing antibodies can suppress JAK1-STAT3 signaling. Mol Cancer Ther. 2011 Mar.10(3):481-494. Pubmedid: 21216930. Pmcid: PMC4084653.
  • Bepler G, Dilling TJ, Wagner H, Hazelton T, Williams C, Chen DT, Greenberg H, Walsh F, Simon G, Tanvetyanon T, Chiappori A, Haura E, Stevens C. Phase II trial of induction gemcitabine and carboplatin followed by conformal thoracic radiation to 74 Gy with weekly paclitaxel and carboplatin in unresectable stage III non-small cell lung cancer. J Thorac Oncol. 2011 Mar.6(3):553-558. Pubmedid: 21289520. Pmcid: PMC3839293.
  • Hammerman PS, Sos ML, Ramos AH, Xu C, Dutt A, Zhou W, Brace LE, Woods BA, Lin W, Zhang J, Deng X, Lim SM, Heynck S, Peifer M, Simard JR, Lawrence MS, Onofrio RC, Salvesen HB, Seidel D, Zander T, Heuckmann JM, Soltermann A, Moch H, Koker M, Leenders F, Gabler F, Querings S, Ansén S, Brambilla E, Brambilla C, Lorimier P, Brustugun OT, Helland A, Petersen I, Clement JH, Groen H, Timens W, Sietsma H, Stoelben E, Wolf J, Beer DG, Tsao MS, Hanna M, Hatton C, Eck MJ, Janne PA, Johnson BE, Winckler W, Greulich H, Bass AJ, Cho J, Rauh D, Gray NS, Wong KK, Haura EB, Thomas RK, Meyerson M. Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discov. 2011 Jun.1(1):78-89. Pubmedid: 22328973. Pmcid: PMC3274752.
  • Pillai S, Rizwani W, Li X, Rawal B, Nair S, Schell MJ, Bepler G, Haura E, Coppola D, Chellappan S. ID1 facilitates the growth and metastasis of non-small cell lung cancer in response to nicotinic acetylcholine receptor and epidermal growth factor receptor signaling. Mol Cell Biol. 2011 Jul.31(14):3052-3067. Pubmedid: 21606196. Pmcid: PMC3133413.
  • Haura EB, Müller A, Breitwieser FP, Li J, Grebien F, Colinge J, Bennett KL. Using iTRAQ combined with tandem affinity purification to enhance low-abundance proteins associated with somatically mutated EGFR core complexes in lung cancer. J Proteome Res. 2011 Jan.10(1):182-190. Pubmedid: 20945942. Pmcid: PMC3017669.
  • Zhang G, Fang B, Liu RZ, Lin H, Kinose F, Bai Y, Oguz U, Remily-Wood ER, Li J, Altiok S, Eschrich S, Koomen J, Haura EB. Mass spectrometry mapping of epidermal growth factor receptor phosphorylation related to oncogenic mutations and tyrosine kinase inhibitor sensitivity. J Proteome Res. 2011 Jan.10(1):305-319. Pubmedid: 21080693. Pmcid: PMC3050523.
  • Dasgupta P, Rizwani W, Pillai S, Davis R, Banerjee S, Hug K, Lloyd M, Coppola D, Haura E, Chellappan SP. ARRB1-mediated regulation of E2F target genes in nicotine-induced growth of lung tumors. J Natl Cancer Inst. 2011 Feb.103(4):317-333. Pubmedid: 21212384. Pmcid: PMC3039728.
  • Tang H, Yan C, Cao J, Sarma JV, Haura EB, Wu M, Gao H. An essential role for Stat3 in regulating IgG immune complex-induced pulmonary inflammation. Faseb J. 2011 Dec.25(12):4292-4300. Pubmedid: 21859893. Pmcid: PMC3236634.
  • Chen DT, Hsu YL, Fulp WJ, Coppola D, Haura EB, Yeatman TJ, Cress WD. Prognostic and predictive value of a malignancy-risk gene signature in early-stage non-small cell lung cancer. J Natl Cancer Inst. 2011 Dec.103(24):1859-1870. Pubmedid: 22157961. Pmcid: PMC3243673.
  • Remily-Wood ER, Liu RZ, Xiang Y, Chen Y, Thomas CE, Rajyaguru N, Kaufman LM, Ochoa JE, Hazlehurst L, Pinilla-Ibarz J, Lancet J, Zhang G, Haura E, Shibata D, Yeatman T, Smalley KS, Dalton WS, Huang E, Scott E, Bloom GC, Eschrich SA, Koomen JM. A database of reaction monitoring mass spectrometry assays for elucidating therapeutic response in cancer. Proteom Clin Appl. 2011 Aug.5(7-8):383-396. Pubmedid: 21656910. Pmcid: PMC3530891.
  • Fang B, Haura EB, Smalley KS, Eschrich SA, Koomen JM. Methods for investigation of targeted kinase inhibitor therapy using chemical proteomics and phosphorylation profiling. Biochem Pharmacol. 2010 Sep.80(5):739-747. Pubmedid: 20361944. Pmcid: PMC2995952.
  • Yoshida T, Zhang G, Haura EB. Targeting epidermal growth factor receptor: central signaling kinase in lung cancer. Biochem Pharmacol. 2010 Sep.80(5):613-623. Pubmedid: 20519133.
  • Machida K, Eschrich S, Li J, Bai Y, Koomen J, Mayer BJ, Haura EB. Characterizing tyrosine phosphorylation signaling in lung cancer using SH2 profiling. PLoS One. 2010 Oct.5(10):e13470. Pubmedid: 20976048. Pmcid: PMC2957407.
  • Ren Y, Chen Z, Chen L, Fang B, Win-Piazza H, Haura E, Koomen JM, Wu J. Critical role of Shp2 in tumor growth involving regulation of c-Myc. Genes Cancer. 2010 Oct.1(10):994-1007. Pubmedid: 21442024. Pmcid: PMC3063420.
  • Haura EB, Sommers E, Song L, Chiappori A, Becker A. A pilot study of preoperative gefitinib for early-stage lung cancer to assess intratumor drug concentration and pathways mediating primary resistance. J Thorac Oncol. 2010 Nov.5(11):1806-1814. Pubmedid: 20881637. Pmcid: PMC4120062.
  • Kim LC, Rix U, Haura EB. Dasatinib in solid tumors. Expert Opin Inv Drug. 2010 Mar.19(3):415-425. Pubmedid: 20113198.
  • Haura EB, Tanvetyanon T, Chiappori A, Williams C, Simon G, Antonia S, Gray J, Litschauer S, Tetteh L, Neuger A, Song L, Rawal B, Schell MJ, Bepler G. Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancer. J Clin Oncol. 2010 Mar.28(8):1387-1394. Pubmedid: 20142592. Pmcid: PMC3040065.
  • Haura EB, Camidge DR, Reckamp K, Chiappori A, Johnson F, Herbst R, Wong K, Carbone D. Molecular origins of lung cancer: prospects for personalized prevention and therapy. J Thorac Oncol. 2010 Jun.5(6 Suppl 3):S207-S213. Pubmedid: 20502275.
  • Tanvetyanon T, Robinson L, Sommers KE, Haura E, Kim J, Altiok S, Bepler G. Relationship between tumor size and survival among patients with resection of multiple synchronous lung cancers. J Thorac Oncol. 2010 Jul.5(7):1018-1024. Pubmedid: 20453687.
  • Rothschild SI, Gautschi O, Haura EB, Johnson FM. Src inhibitors in lung cancer: current status and future directions. Clin Lung Cancer. 2010 Jul.11(4):238-242. Pubmedid: 20630825.
  • Brazelle W, Kreahling JM, Gemmer J, Ma Y, Cress WD, Haura E, Altiok S. Histone deacetylase inhibitors downregulate checkpoint kinase 1 expression to induce cell death in non-small cell lung cancer cells. PLoS One. 2010 Dec.5(12):e14335. Pubmedid: 21179472. Pmcid: PMC3001870.
  • Li J, Rix U, Fang B, Bai Y, Edwards A, Colinge J, Bennett KL, Gao J, Song L, Eschrich S, Superti-Furga G, Koomen J, Haura EB. A chemical and phosphoproteomic characterization of dasatinib action in lung cancer. Nat Chem Biol. 2010 Apr.6(4):291-299. Pubmedid: 20190765. Pmcid: PMC2842457.
  • Haura EB, Ricart AD, Larson TG, Stella PJ, Bazhenova L, Miller VA, Cohen RB, Eisenberg PD, Selaru P, Wilner KD, Gadgeel SM. A phase II study of PD-0325901, an oral MEK inhibitor, in previously treated patients with advanced non-small cell lung cancer. Clin Cancer Res. 2010 Apr.16(8):2450-2457. Pubmedid: 20332327.
  • Gao J, Zheng Z, Rawal B, Schell MJ, Bepler G, Haura EB. Mirk/Dyrk1B, a novel therapeutic target, mediates cell survival in non-small cell lung cancer cells. Cancer Biol Ther. 2009 Sep.8(17):1671-1679. Pubmedid: 19633423. Pmcid: PMC3839311.
  • Kim LC, Song L, Haura EB. Src kinases as therapeutic targets for cancer. Nat Rev Clin Oncol. 2009 Oct.6(10):587-595. Pubmedid: 19787002.
  • Davis R, Rizwani W, Banerjee S, Kovacs M, Haura E, Coppola D, Chellappan S. Nicotine promotes tumor growth and metastasis in mouse models of lung cancer. PLoS One. 2009 Oct.4(10):e7524. Pubmedid: 19841737. Pmcid: PMC2759510.
  • Dasgupta P, Rizwani W, Pillai S, Kinkade R, Kovacs M, Rastogi S, Banerjee S, Carless M, Kim E, Coppola D, Haura E, Chellappan S. Nicotine induces cell proliferation, invasion and epithelial-mesenchymal transition in a variety of human cancer cell lines. Int J Cancer. 2009 Jan.124(1):36-45. Pubmedid: 18844224. Pmcid: PMC2826200.
  • Gao J, McConnell MJ, Yu B, Li J, Balko JM, Black EP, Johnson JO, Lloyd MC, Altiok S, Haura EB. MUC1 is a downstream target of STAT3 and regulates lung cancer cell survival and invasion. Int J Oncol. 2009 Aug.35(2):337-345. Pubmedid: 19578748. Pmcid: PMC4098131.
  • Koomen JM, Haura EB, Bepler G, Sutphen R, Remily-Wood ER, Benson K, Hussein M, Hazlehurst LA, Yeatman TJ, Hildreth LT, Sellers TA, Jacobsen PB, Fenstermacher DA, Dalton WS. Proteomic contributions to personalized cancer care. Mol Cell Proteomics. 2008 Oct.7(10):1780-1794. Pubmedid: 18664563. Pmcid: PMC2559938.
  • Bepler G, Sommers KE, Cantor A, Li X, Sharma A, Williams C, Chiappori A, Haura E, Antonia S, Tanvetyanon T, Simon G, Obasaju C, Robinson LA. Clinical efficacy and predictive molecular markers of neoadjuvant gemcitabine and pemetrexed in resectable non-small cell lung cancer. J Thorac Oncol. 2008 Oct.3(10):1112-1118. Pubmedid: 18827606. Pmcid: PMC2639211.
  • Simon GR, Extermann M, Chiappori A, Williams CC, Begum M, Kapoor R, Haura EB, Ismail-Khan R, Schell MJ, Antonia SJ, Bepler G. Phase 2 trial of docetaxel and gefitinib in the first-line treatment of patients with advanced nonsmall-cell lung cancer (NSCLC) who are 70 years of age or older. Cancer. 2008 May.112(9):2021-2029. Pubmedid: 18300255.
  • Li J, Viallet J, Haura EB. A small molecule pan-Bcl-2 family inhibitor, GX15-070, induces apoptosis and enhances cisplatin-induced apoptosis in non-small cell lung cancer cells. Cancer Chemother Pharmacol. 2008 Mar.61(3):525-534. Pubmedid: 17505826.
  • Chiappori AA, Haura E, Rodriguez FA, Boulware D, Kapoor R, Neuger AM, Lush R, Padilla B, Burton M, Williams C, Simon G, Antonia S, Sullivan DM, Bepler G. Phase I/II study of atrasentan, an endothelin A receptor antagonist, in combination with paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer. Clin Cancer Res. 2008 Mar.14(5):1464-1469. Pubmedid: 18316570.
  • Lu D, Liu RZ, Izumi V, Fenstermacher D, Haura EB, Koomen J, Eschrich SA. IPEP: an in silico tool to examine proteolytic peptides for mass spectrometry. Bioinformatics. 2008 Dec.24(23):2801-2802. Pubmedid: 18842605.
  • Edwards A, Li J, Atadja P, Bhalla K, Haura EB. Effect of the histone deacetylase inhibitor LBH589 against epidermal growth factor receptor-dependent human lung cancer cells. Mol Cancer Ther. 2007 Sep.6(9):2515-2524. Pubmedid: 17876048.
  • Li J, Yu B, Song L, Eschrich S, Haura E. Effects of IFN-gamma and Stat1 on gene expression, growth, and survival in non-small cell lung cancer cells. J Interferon Cytokine Res. 2007 Mar.27(3):209-220. Pubmedid: 17348819.
  • Simon G, Sharma A, Li X, Hazelton T, Walsh F, Williams C, Chiappori A, Haura E, Tanvetyanon T, Antonia S, Cantor A, Bepler G. Feasibility and efficacy of molecular analysis-directed individualized therapy in advanced non-small-cell lung cancer. J Clin Oncol. 2007 Jul.25(19):2741-2746. Pubmedid: 17602079.
  • Zheng Z, Chen T, Li X, Haura E, Sharma A, Bepler G. DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med. 2007 Feb.356(8):800-808. Pubmedid: 17314339.
  • de Lima Lopes G, Chiappori A, Simon G, Haura E, Sullivan D, Antonia S, Langevin M, Lush R, Rocha-Lima CM. Phase I study of carboplatin in combination with gemcitabine and irinotecan in patients with solid tumors: preliminary evidence of activity in small cell and neuroendocrine carcinomas. Cancer. 2007 Apr.109(7):1413-1419. Pubmedid: 17326096.
  • Haura E. Is repetitive wounding and bone marrow-derived stem cell mediated-repair an etiology of lung cancer development and dissemination?. Med Hypotheses. 2006 Oct.67(4):951-956. Pubmedid: 16714090.
  • Balko J, Potti A, Saunders C, Stromberg A, Haura E, Black E. Gene expression patterns that predict sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer cell lines and human lung tumors. BMC Genomics. 2006 Nov.7:289. Pubmedid: 17096850. Pmcid: PMC1660550.
  • Song L, Morris M, Bagui T, Lee FY, Jove R, Haura EB. Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival. Cancer Res. 2006 Jun.66(11):5542-5548. Pubmedid: 16740687.
  • Haura EB. SRC and STAT pathways. J Thorac Oncol. 2006 Jun.1(5):403-405. Pubmedid: 17409890.
  • Haura E, Livingston S, Coppola D. Autocrine interleukin-6/interleukin-6 receptor stimulation in non-small-cell lung cancer. Clin Lung Cancer. 2006 Jan.7(4):273-275. Pubmedid: 16512982.
  • Dasgupta P, Rastogi S, Pillai S, Ordonez-Ercan D, Morris M, Haura E, Chellappan S. Nicotine induces cell proliferation by beta-arrestin-mediated activation of Src and Rb-Raf-1 pathways. J Clin Invest. 2006 Aug.116(8):2208-2217. Pubmedid: 16862215. Pmcid: PMC1513051.
  • Dasgupta P, Kinkade R, Joshi B, Decook C, Haura E, Chellappan S. Nicotine inhibits apoptosis induced by chemotherapeutic drugs by up-regulating XIAP and survivin. Proc Natl Acad Sci U S A. 2006 Apr.103(16):6332-6337. Pubmedid: 16601104. Pmcid: PMC1458878.
  • Chiappori A, Simon G, Williams C, Haura E, Rocha-Lima C, Wagner H, Bepler G, Antonia S. Phase II study of first-line sequential chemotherapy with gemcitabine-carboplatin followed by docetaxel in patients with advanced non-small cell lung cancer. Oncology-Basel. 2005 Sep.68(4-6):382-390. Pubmedid: 16020967.
  • Dauer D, Ferraro B, Song L, Yu B, Mora L, Buettner R, Enkemann S, Jove R, Haura E. Stat3 regulates genes common to both wound healing and cancer. Oncogene. 2005 May.24(21):3397-3408. Pubmedid: 15735721.
  • Ferraro B, Bepler G, Sharma S, Cantor A, Haura E. EGR1 predicts PTEN and survival in patients with non-small-cell lung cancer. J Clin Oncol. 2005 Mar.23(9):1921-1926. Pubmedid: 15774784.
  • Song L, Coppola D, Livingston S, Cress D, Haura EB. Mcl-1 regulates survival and sensitivity to diverse apoptotic stimuli in human non-small cell lung cancer cells. Cancer Biol Ther. 2005 Mar.4(3):267-276. Pubmedid: 15753661.
  • Haura E, Turkson J, Jove R. Mechanisms of disease: Insights into the emerging role of signal transducers and activators of transcription in cancer. Nat Clin Pract Oncol. 2005 Jun.2(6):315-324. Pubmedid: 16264989.
  • Zheng Z, Bepler G, Cantor A, Haura EB. Small tumor size and limited smoking history predicts activated epidermal growth factor receptor in early-stage non-small cell lung cancer. Chest. 2005 Jul.128(1):308-316. Pubmedid: 16002951.
  • Freeman S, Bepler G, Haura E, Sutphen R, Cress W. Re: Prognostic significance of a short sequence insertion in the MCL-1 promoter in chronic lymphocytic leukemia. J Natl Cancer Inst. 2005 Jul.97(14):1088-1089. Pubmedid: 16030308.
  • Bepler G, Zheng Z, Gautam A, Sharma S, Cantor A, Cress W, Kim Y, Rosell R, McBride C, Robinson L, Sommers E, Haura E. Ribonucleotide reductase M1 gene promoter activity, polymorphisms, population frequencies, and clinical relevance. Lung Cancer. 2005 Feb.47(2):183-192. Pubmedid: 15639717.
  • Haura EB, Zheng Z, Song L, Cantor A, Bepler G. Activated epidermal growth factor receptor-Stat-3 signaling promotes tumor survival in vivo in non-small cell lung cancer. Clin Cancer Res. 2005 Dec.11(23):8288-8294. Pubmedid: 16322287.
  • Haura EB, Cress WD, Chellappan S, Zheng Z, Bepler G. Antiapoptotic signaling pathways in non-small-cell lung cancer: biology and therapeutic strategies. Clin Lung Cancer. 2004 Sep.6(2):113-122. Pubmedid: 15476597.
  • Bepler G, Sharma S, Cantor A, Gautam A, Haura E, Simon G, Sharma A, Sommers E, Robinson L. RRM1 and PTEN as prognostic parameters for overall and disease-free survival in patients with non-small-cell lung cancer. J Clin Oncol. 2004 May.22(10):1878-1885. Pubmedid: 15143080.
  • Turkson J, Kim JS, Zhang S, Yuan J, Huang M, Glenn M, Haura E, Sebti S, Hamilton AD, Jove R. Novel peptidomimetic inhibitors of signal transducer and activator of transcription 3 dimerization and biological activity. Mol Cancer Ther. 2004 Mar.3(3):261-269. Pubmedid: 15026546.
  • D'Amato G, Rocha Lima C, Mahany JJ, Muro-Cacho C, Haura EB. Neutropenic enterocolitis (typhilitis) associated with docetaxel therapy in a patient with non-small-cell lung cancer: case report and review of literature. Lung Cancer. 2004 Jun.44(3):381-390. Pubmedid: 15140552.
  • Hauser P, Ma L, Agrawal D, Haura E, Cress WD, Pledger WJ. Efficient down-regulation of cyclin A-associated activity and expression in suspended primary keratinocytes requires p21(Cip1). Mol Cancer Res. 2004 Feb.2(2):96-104. Pubmedid: 14985466.
  • Howard B, Zheng Z, Campa M, Wang M, Sharma A, Haura E, Herndon JE 2nd, Fitzgerald M, Bepler G, Patz EF J. Translating biomarkers into clinical practice: prognostic implications of cyclophilin A and macrophage migratory inhibitory factor identified from protein expression profiles in non-small cell lung cancer. Lung Cancer. 2004 Dec.46(3):313-323. Pubmedid: 15541816.
  • Simon G, Ruckdeschel J, Williams C, Cantor A, Antonia S, Haura E, Rocha C, Chiappori A, Wagner H, Robinson L, Sommers E, Alberts M, Bepler G. Gefitinib (ZD1839) in previously treated advanced non-small-cell lung cancer: experience from a single institution. Cancer Control. 2003 Sep.10(5):388-395. Pubmedid: 14581894.
  • Haura EB, Sotomayor E, Antonia SJ. Gene therapy for lung cancer. Mol Biotechnol. 2003 Oct.25(2):139-148. Pubmedid: 14526124.
  • Bagui TK, Mohapatra S, Haura E, Pledger WJ. P27Kip1 and p21Cip1 are not required for the formation of active D cyclin-cdk4 complexes. Mol Cell Biol. 2003 Oct.23(20):7285-7290. Pubmedid: 14517297. Pmcid: PMC230308.
  • Song L, Turkson J, Karras JG, Jove R, Haura EB. Activation of Stat3 by receptor tyrosine kinases and cytokines regulates survival in human non-small cell carcinoma cells. Oncogene. 2003 Jul.22(27):4150-4165. Pubmedid: 12833138.
  • Ma Y, Cress WD, Haura EB. Flavopiridol-induced apoptosis is mediated through up-regulation of E2F1 and repression of Mcl-1. Mol Cancer Ther. 2003 Jan.2(1):73-81. Pubmedid: 12533675.
  • Haura EB, Sotomayor E, Antonia SJ. Gene therapy for lung cancer. An introduction. Methods Mol Med. 2003.75:529-543. Pubmedid: 12407762.
  • Haura E, Winden M, Proia A, Trotter J. Fulminant hepatic failure due to disseminated adenovirus infection in a patient with chronic lymphocytic leukemia. Cancer Control. 2002 May.9(3):248-253. Pubmedid: 12060822.
  • Niu G, Wright KL, Huang M, Song L, Haura E, Turkson J, Zhang S, Wang T, Sinibaldi D, Coppola D, Heller R, Ellis LM, Karras J, Bromberg J, Pardoll D, Jove R, Yu H. Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene. 2002 Mar.21(13):2000-2008. Pubmedid: 11960372.
  • Haura E. Management of advanced non-small cell lung cancer: current trends. Curr Opin Pulm Med. 2002 Jul.8(4):251-256. Pubmedid: 12055385.
  • Croxton R, Ma Y, Song L, Haura E, Cress W. Direct repression of the Mcl-1 promoter by E2F1. Oncogene. 2002 Feb.21(9):1359-1369. Pubmedid: 11857079.
  • Sarries C, Haura E, Roig B, Taron M, Abad A, Scagliotti G, Rosell R. Pharmacogenomic strategies for developing customized chemotherapy in non-small cell lung cancer. Pharmacogenomics. 2002.3(6):763-780. Pubmedid: 12437479.
  • Turkson J, Ryan D, Kim J, Zhang Y, Chen Z, Haura E, Laudano A, Sebti S, Hamilton A, Jove R. Phosphotyrosyl peptides block Stat3-mediated DNA binding activity, gene regulation, and cell transformation. J Biol Chem. 2001 Nov.276(48):45443-45455. Pubmedid: 11579100.
  • Haura E. Treatment of advanced non-small-cell lung cancer: a review of current randomized clinical trials and an examination of emerging therapies. Cancer Control. 2001 Jul.8(4):326-336. Pubmedid: 11483886.
  • Sears R, Nuckolls F, Haura E, Nevins J. Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability. Genes Dev. 2000 Oct.14(19):2501-2514. Pubmedid: 11018017.

Grants

Title: St of FL Appropriation-Lung CoE Developmental Funds-11
Sponsor: State of Florida
PI (Contact): Cleveland, J., PI (MPI): Haura, E.
Title: Developing CDK12 inhibitors to overcome therapy resistance in HER2+ and KRAS driven breast and lung cancers
Sponsor: Nat Institutes of Health
PI (Contact): Duckett, D., PI (MPI): Monastyrskyi, A., PI (MPI): Haura, E.
Title: Exploring Correlation Between RTK Activation Status and KRAS G12C(ON) Inhibitor Sensitivity, and Developing New PLA Assays to Inform RAS and mTOR Pathways
Sponsor: Revolution Medicines Inc
PI: Haura, E.
Title: Identifying Metabolic Vulnerabilities in Lung Cancer
Sponsor: Nat Institutes of Health
PI (Contact): Flores, E., PI (MPI): Haura, E., Project PI: DeNicola, G., Project PI: Rodriguez, P., Project PI: Cleveland, J., Core PI/Director: Fridley, B., Core PI/Director: Cress, D., Core PI/Director: Koomen, J.
Title: Lung Cancer Diagnostic Testing Program
Sponsor: The Salah Foundation
PI: Haura, E.
Title: Exploring Correlation Between EGFR/MET Activation Status and RMC-4630 Sensitivity in Tumor Tissue Using PLA Assays
Sponsor: Revolution Medicines Inc
PI: Haura, E.
Title: Validation of EGFR Protein Complexes as Molecular Diagnostics
Sponsor: Nat Institutes of Health
PI: Haura, E.
Title: Targeting Bidirectional Signaling in Lung Stroma and Cancer Stems
Sponsor: Nat Institutes of Health
PI (Contact): Rix, U., PI (MPI): Haura, E.
Title: Precision Lung Cancer Therapy Design Through Multiplexed Adapter Measurement
Sponsor: Nat Institutes of Health
PI (MPI): Haura, E.

Patient Comments
Overall Satisfaction
4.8
★★★★★
★★★★★

17 patients rated this provider

The Provider Rating is an average of all responses to specific care provider-related questions from our nationally-recognized Press Ganey Patient Satisfaction Survey. These surveys assess the experience of our patients when visiting us for an Outpatient Clinic, Urgent Care or Virtual Health (Telemedicine) visit. Responses are measured on a scale of 1 to 5 with 5 being the best score.

Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.

Learn more about our patient satisfaction survey

Comments ()

Comments are gathered from specific care provider-related questions from our Patient Satisfaction Survey . The comments are submitted by patients and reflect their views and opinions. Patients are de-identified for confidentiality and patient privacy.

We post both positive and negative comments from the surveys. We do not post comments that are libelous, slanderous, profane, irrelevant or otherwise inappropriate or may risk the privacy of our patients. A “[…]” in the comments below indicates de-identified patient information or comments that are unrelated to the patient’s experience with the visit to the provider, such as comments related to another provider, about the survey itself, or otherwise completely off-topic.

Not all providers will have a star rating or comments. In order to ensure accuracy of our ratings, we only display ratings for providers who have a minimum of 30 completed from the previous 12 months.

Learn more about our patient comments

Provider Ratings and comments are gathered from our nationally-recognized Press Ganey Patient Satisfaction Survey. If a provider does not have ratings or comments listed it can be for several reasons, including:

  • The provider has not yet received the minimum number of patient satisfaction surveys to be eligible for display. We require a minimum of 30 surveys before we post results to ensure that the rating is statistically reliable and a true reflection of patient satisfaction.
  • He or she may be a researcher or other type of provider that does not see patients.
  • The provider practices in a specialty or office that does not use the specified surveys currently used for these ratings.
Learn more about our patient satisfaction survey, ratings and comments